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 A key requirement of the retroviral lifecycle is integration of the proviral genome 
into the host cell genome. This makes retroviral vectors uniquely suited for gene therapy 
applications. While murine leukemia virus (MLV) and human immunodeficiency virus-1 
(HIV-1) based vectors are commonly used, we propose that avian leukosis virus (ALV) 
may be a safer vector. Previous gene therapy trials, while successful, had issues with 
integration into and activation of oncogenes leading to the formation of cancer. In this 
thesis, we show that ALV integration is relatively random with only slight integration site 
preferences in the chicken genome, potentially making it less prone to insertional 
mutagenesis. 
 To better understand how this random integration pattern is achieved, we also 
determine host cell factors that regulate ALV integration. Host proteins have previously 
been shown to target integration of MLV and HIV-1 to transcription start sites and active 
genes respectively. We show here that the cellular FACT (facilitates chromatin 
transcription) complex proteins regulate ALV integration efficiency in vitro and in vivo 
by binding directly to the ALV integrase protein. We show that the integration pattern of 
ALV in vivo changes significantly with varying expression levels of FACT complex. We 
hypothesize based on the observed direct binding of the FACT complex to the integrase 
protein and the observed effect in vivo, that the FACT complex may be acting as a 
bimodal tether to recruit the ALV pre-integration complex to specific genomic locations, 
thereby influencing both efficiency and pattern of integration. 
 We also explore other host cell protein candidates that selectively bound the ALV 




known to regulate MLV integration, also seem to have an effect on ALV integration 
efficiency in vivo. We also see subtle effects of BET protein inhibition on integration 
targeting. Interestingly, BET protein inhibition in a FACT knockdown background has 
the largest effect on integration targeting suggesting a potential collaborative effect of the 
cellular host factors. Other factors explored, such as nucleolin and UBTF (upstream 
binding transcription factor) were found to regulate the ALV lifecycle but not directly at 
the level of integration.  
 In addition to analyzing the regulation of ALV integration, this thesis also 
documents how the subsequent selection of integration sites in vivo can be used to 
identify novel genes involved in tumorigenesis. Because retroviruses contain strong 
promoter and enhancer elements, the insertion of the proviral genome into the host cell 
genome can have profound effects on host gene expression. Depending on the site of 
integration, this can activate gene expression or promote the expression of altered gene 
products. In vivo, integration sites into genes that contribute to the regulation of 
proliferation, immortalization or apoptosis are selected for over time and can lead to the 
formation of tumors. We identified selected, or expanded, integration sites in B-cell 
lymphomas. This led to the identification of novel oncogenes CTDSPL and CTDSPL2 as 
well as the putative noncoding TAPAS RNA. 
 CTDSPL and CTDSPL2 have been previously shown to regulate the 
phosphorylation status of the C-terminal domain of RNA polymerase II. They also play a 
role in regulating pRb phosphorylation and thus have been previously characterized as 
tumor suppressor genes. To the contrary, in our system we observe that CTDSPL and 




migration and protect cells against apoptosis, attributes more characteristic of an 
oncogene. Truncated proteins, like those generated by ALV integration within CTDSPL 
and CTDSPL2 in tumors, also promote immortalization in primary cell culture. Thus, we 
hypothesize that integrations into these genes were selected for in tumors due to the 
immortalization role of the truncated protein products. 
 The most common expanded integration site identified in B-cell lymphomas was 
in the TERT (telomerase reverse transcriptase) promoter region. We found that these 
integrations were predominantly in the opposite transcriptional orientation to TERT and 
were in fact promoting the expression of a truncated form of a novel antisense long 
noncoding RNA, which we have named TAPAS (TERT antisense promoter associated) 
RNA. TAPAS RNA is conserved in most birds and we find evidence for a similar 
transcript in humans. We provide evidence here for a role of TAPAS RNA in regulating 
TERT expression in cis in both chickens and humans. 
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1.1 Research Objectives 
 My thesis work has been divided into two major areas of study concerning avian 
leukosis virus (ALV) integration. The first goal of my work was to gain a better 
understanding of the integration pattern of ALV and how it differs from other 
retroviruses. In addition, I attempted to understand the cellular host factors that regulate 
integration and determine ALV integration site selection in vivo. 
 The goal of my second project was to identify novel players in oncogenesis using 
ALV as an insertional mutagenesis tool. Making use of high throughput sequencing of 
multiple ALV-induced tumors we identify genes that harbor clonally expanded, recurrent 
integrations and subsequently characterize the role of these genes in oncogenesis.  
1.2 Retroviral classification 
 Avian leukosis virus (ALV) belongs to the retroviridae family, which consists of 
viruses with a single strand RNA genome that utilize a DNA intermediate to replicate. 
The family consists of seven genera, alpha- through epsilon-retrovirus, lenti- and 
spumavirus. Retroviruses are ascribed to a genera based on sequence relatedness of a 
designated portion of the reverse transcriptase open reading frame, found to be the most 
conserved region amongst retroviral family members. Other criteria to classify 
retroviruses include virion core morphology as well as the presence of accessory open 
reading frames. For instance, alpharetroviruses and gammaretroviruses have been 
classified as simple retroviruses due to the presence of only the common core retroviral 
genes – gag, pol and env, whereas HIV-1 has been classified as a “complex” retrovirus 





1.3 Genome structure and organization 
As mentioned, ALV is a simple retrovirus with just the three open reading frames 
– gag, pol and env – which are common to all retroviruses. The gag gene of ALV 
encodes the structural proteins matrix (MA), capsid (CA) and nucleocapsid (NC) as well 
as the protease (PR) enzyme. The matrix protein, encoded by the N-terminal portion of 
gag, associates with the lipid membrane of the cell and is important in virion assembly 
(Hamard-Peron and Muriaux, 2011). The capsid protein forms the structural protein core 
that encapsidates the RNA genome. Nucleocapsid is a small (60-90 amino acids) basic 
protein that coats the viral RNA genome. NC plays important roles in facilitating the 
annealing of tRNA to the primer binding site as well as in formation of the dimeric RNA 
genome (Feng et al., 1996). NC mutations have also been reported to block RNA 
packaging implicating the protein in virion assembly as well (Darlix et al., 2014). The 
protease protein is required for proteolytic cleavage of the viral polyprotein during virion 
maturation (Coffin et al., 1997). 
 pol encodes the reverse transcriptase (RT) and integrase (IN) enzymes. The RT 
protein possesses reverse transcriptase catalytic activity as well as RNase H activity, both 
of which are required for catalyzing reverse transcription of the viral RNA genome to a 
double stranded DNA genome. The coding sequence of RT is one of the most conserved 
sequences amongst retroviruses. However, despite conservation, the active subunit 
structure differs between genera. For instance, in ALV, RT functions as a heterodimer 
with one dimer consisting of only the polymerase and RNase H domains and the larger 
subunit consisting of an additional fused integrase (IN) domain. HIV-1 RT likewise 




one subunit possessing both polymerase and RNase H catalytic activity. MLV RT on the 
other hand is able to function as a monomer.  
The env mRNA forms from the splicing of the viral leader sequence, in the 
extreme N terminus of gag (+18 nt), to a splice acceptor site in env. Env encodes the 
surface glycoprotein (SU) and transmembrane (TM) protein of the virion. Because these 
glycoproteins bind cellular surface proteins, they are responsible for determining the host 
cell range of the retroviruses (Coffin et al., 1997). 
Lastly, the viral genome is flanked by long terminal repeats (LTRs) that contain 
strong promoter and enhancer elements to drive the expression of viral genes (Coffin et 
al., 1997). A portion of the LTR sequences are also required for integration. 
1.4 Retroviral life cycle 
 When a virion approaches a susceptible host cell, binding of the viral surface 
glycoprotein to an appropriate host cell receptor triggers endosomal uptake of the virion. 
Upon acidification of the endosome, fusion of the viral envelope and host cell membrane 
occurs leading to the release of the viral capsid into the cellular cytoplasm (Barnard and 
Young, 2003). Once in the cytoplasm reverse transcription of the viral RNA by the viral 
RT protein begins, converting the RNA genome into a double stranded DNA copy 
utilizing a virally packaged tRNA primer and cytoplasmic dNTPs (Coffin et al., 1997). In 
the case of ALV specifically, reverse transcription is completed in the nucleus (Werner et 
al., 2002).  
 The preintegration complex (PIC) forms near the end of reverse transcription in the 
cytoplasm and consists of the critical viral integrase (IN) protein as well as other viral 




are poorly understood due to the low abundance of the PIC during infection (i.e. one copy 
per cell) (Engelman and Cherepanov, 2017).  
 Depending on the family of retrovirus, breakdown of the nuclear membrane may be 
required for the retroviral PIC to access the host genomic DNA. This is true of most 
simple retroviruses, such as murine leukemia virus (MLV). However, more complex 
retroviruses, such as HIV-1, are able to infect non-dividing cells. The PIC of HIV-1 is 
known minimally to contain MA protein as well as an HIV-1 specific accessory protein, 
Vpr, both of which possess nuclear localization signals (NLS) and thus are believed to 
contribute to the active transport of the PIC into the nucleus (Gallay et al., 1995; 
Heinzinger et al., 1994). More recently, the HIV-1 integrase protein was found to also 
facilitate nuclear import both by possessing an NLS of its own and recruiting MA to the 
PIC (Gallay et al., 1997). Further, differences in time of capsid uncoating of the viral 
genome may play a role in viral ability to enter the nucleus of nondividing cells. HIV-1 
has been shown to uncoat early in the life cycle, at the time of reverse transcription, 
whereas MLV capsid remains associated with the viral genome until at least nuclear entry 
(Fassati, 2006; Yamashita and Emerman, 2006). 
 ALV exhibits an intermediate phenotype between that of MLV and HIV-1 
(Hatziioannou and Goff, 2001). ALV is able to infect nondividing cells significantly 
better than MLV, but still with a decreased efficiency as compared to HIV-1. Similar to 
HIV-1, the IN of ALV has been found to possess an NLS, which could explain the ability 
of ALV to transduce nondividing cells. The discrepancy between the efficiency of HIV-1 
and ALV import could be due to the presence of multiple NLS in PIC components of 




the proviral DNA genome into the host cell genome occurs catalyzed by the virally 


























Figure 1.1: Early steps of retroviral life cycle. (1) Surface glycoproteins of the virion 
bind to a compatible receptor on the surface of the host cell. (2) This binding triggers 
either endosomal uptake of the virion or membrane fusion, releasing the virion capsid 
into the cytoplasm. (3) Reverse transcription by the virally packaged RT protein converts 
a dimeric single strand RNA genome into a dsDNA copy. The dsDNA copy of the 
genome remains in complex with RT, IN, CA and other viral proteins to form the pre-
integration complex (PIC) (4). (5) The PIC gains access to the nucleus of the host cell 
either by active import or nuclear membrane breakdown. (6) Integration into the host cell 





 After integration, the viral genome is transcribed and translated as a cellular gene by 
RNA polymerase II and ribosomes respectively. Gag and Pol are translated as a 
polyprotein whereas Env gets translated from a subgenomic mRNA. However, in ALV 
the gag and pol genes are in different open reading frames and thus, to get translation of 
the full Gag-Pol polyprotein, a programmed ribosomal frameshift is required. The 
frameshifting event occurs in only a small proportion of total translation events thus 
ensuring a high Gag to Gag-Pol ratio (Shu-Yun Le et al., 1991). This has been shown to 
be important for efficient viral replication (Dinman et al., 2002). 
 After translation of viral proteins, the process of assembly and particle budding is 
coordinated largely by the Gag protein. The N-terminal portion of Gag is required for 
proper targeting of both Gag and Gag-Pol proteins to the cellular plasma membrane. The 
NC portion of the Gag polyprotein is thought to be important for selective packaging of 
the viral RNA genome (Lu et al., 2011). Further, a number of cellular RNAs get 
packaged in the virion as well. However, the specific tRNA required to prime reverse 
transcription is enriched amongst packaged cellular RNAs. Data shows that the RT 
protein mediates the selective packaging of the appropriate tRNA primer (Cen et al., 
2002). 
 The process by which Env proteins are specifically directed to the site of virion 
assembly is largely unknown. It is thought that Gag may also play a role in this process 
via the MA protein, which has been shown to bind the TM protein of Env. Budding of the 
assembled virion is dependent on Gag alone. After budding, the proteolytic processing of 
the Gag and Gag-Pol precursor proteins within the virion by viral protease (PR) is 




1.5 Importance of the viral integrase protein 
 A unique feature of retroviruses is their ability to integrate their cDNA genome into 
the host cell genome. Once integrated into the host cell genome, the provirus persists 
indefinitely and is passed to daughter cells via cell division. Integration is an essential 
step in the retroviral life cycle and requires only the integrase protein and the ends of the 
long terminal repeats that flank the viral genome (Donehower and Varmus, 1984; 
Panganiban and Temin, 1984). Aside from essential functions in integration, integrase 
also plays a pivotal role in various stages of the retroviral life cycle as evidenced by the 
array of phenotypes exhibited by integrase mutants (Engelman, 1999).  
 Integrase mutants have been classified into two categories based on the exhibited 
phenotype. Class I mutants are defined as mutations that directly affect the catalytic 
ability of IN. These include mutations of the IN active site. Direct effects on integrase 
catalytic activity are assessed by the presence of 2-LTR circles. Once thought to be the 
precursor to integration, 2-LTR circles have since been found to be a dead end product of 
failed retroviral integration (Bukrinsky et al., 1993; Panganiban and Temin, 1984). 2-
LTR circles form from unintegrated viral genomes in the nucleus through the host non-
homologous end joining pathway (Li et al., 2001). Thus, mutants that directly inhibit only 
integration will manifest with increased abundance of 2-LTR circles due to the increased 
presence of unintegrated viral genomes in the nucleus. Class II IN mutants on the other 
hand display pleiotropic effects with defects observed in reverse transcription, nuclear 
import and virion maturation (Charmetant et al., 2011; van Gent et al., 1993; Kessl et al., 





1.6 Molecular mechanism of retroviral integration 
 The integrase protein, along with several other viral and cellular proteins, combines 
to form the PIC in the cytoplasm of the host cell. These complexes can be isolated from 
infected cells and have been shown to be capable of mediating integration in vitro 
(Bowerman et al., 1989; Brown et al., 1987). The composition of the PIC varies between 
retroviral genera but is known to consist minimally of viral DNA, and the viral proteins - 
NC, MA, RT, IN, and varying levels of CA.   
 In vitro the viral IN protein alone is capable of catalyzing proviral integration into 
the host cell genome and does so by a two-step mechanism (Katz et al., 1990; Nowotny, 
2009). First, IN cleaves the terminal 2 bases from the 3’ end of the proviral genome 
leaving exposed 3’-OH groups immediately following an invariant CA dinucleotide 
(Figure 1.2A). The 3’ end processing step is required for successful integration and has 
also been shown to be coupled to the formation of a stable integrase-DNA complex (Vink 
et al., 1994). Following viral DNA end processing, the exposed 3’-OH groups attack 
staggered 5’ phosphoryl bonds of opposite strands of target host DNA (Bushman et al., 
1990; Engelman et al., 1991). Both end processing and strand transfer reactions are 
mediated by SN2 transesterification reactions (Engelman et al., 1991).  
 The strand transfer reaction leaves behind single stranded gaps on either strand as 
well as a 2-bp overhang of the viral DNA (Figure 1.2B). Host cell repair mechanisms are 
thought to fill in the gaps that flank the site of integration. In the case of ALV, 
integration, this repair primarily generates a 6-bp repeat sequence flanking the site of 
integration (Hishinuma et al., 1981). The exact host cell machinery that mediates repair 




Figure 1.2: Mechanism of retroviral DNA integration into the host cell genome. (A) 
3’ end processing of viral DNA ends by virally encoded integrase protein. Two 
nucleotides at the 3’ ends of the viral genome, shown in blue, are resected leaving behind 
an invariant CA dinucleotide with an exposed 3’-OH group. (B) Strand transfer reaction. 
Via an SN2 transesterification reaction the exposed 3’-OH groups attack staggered 5’ 
phosphoryl groups of the target DNA sequence. Target DNA cleavage and subsequent 
strand transfer leaves behind a single strand gap and a 2-nt viral sequence overhang that 



























 Integration is analogous to DNA transposition, and retroviral integrase proteins 
belong to a superfamily of DD(E/D) transposases (Nowotny et al., 2009). IN functions as 
a multimer, referred to as the intasome, and the extent of multimerization varies by 
retroviral genus (Engelman and Cherepanov, 2017). The canonically studied model for 
intasome assembly and mechanism of action is the prototype foamy virus (PFV). PFV 
has been found to possess the lowest order IN-to-viral DNA ratio and thus this minimalist 
assembly serves as a straightforward model for understanding intasome architecture and 
function. All retroviral IN proteins consist of three conserved domains. The N-terminal 
domain (NTD), catalytic core domain which harbors the DDE catalytic triad and RNase 
H fold (CCD), and the C-terminal domain (Engelman and Cherepanov, 2017). The PFV 
intasome consists of four IN proteins with an IN dimer binding each of the viral DNA 
ends (Hare et al., 2010). The inner IN molecules provide the active sites to catalyze both 
the 3’ processing and strand transfer reactions. The C-terminal domains of the associated 
IN molecules are required to engage the target DNA (Cherepanov et al., 2011; Maertens 
et al., 2010). Interestingly, all domains of the outer IN subunits are dispensable for 
catalytic activity. 
 The intasome architecture is not strictly conserved and a surprising amount of 
variability in extent of multimerization exists amongst intasomes of different retroviruses. 
The functional integrase multimer of alpharetroviruses (including ALV) and 
betaretroviruses (i.e. MMTV) was found to be an octamer (Ballandras-Colas et al., 2016; 
Yin et al., 2016). The HIV-1 intasome is heterogeneous. There have been reports of a 
functional tetrameric intasome as well as higher order assemblies with up to 16 integrase 




contained in the intasome, the functional organization is tetrameric – for PFV, IN acts as 
a tetramer of monomeric IN proteins; for ALV and MMTV, IN acts as a tetramer of 
dimeric proteins and so on. The mechanism of intasome assembly is not well understood, 
and while the structural features of the intasome have been uncovered for various 
retroviruses, the functional consequences of higher order multimerization remains 
unclear. 
1.7 Proviral integration is regulated by host cell factors 
 While integrase alone can catalyze integration of the proviral genome, host cell 
factors have been found to increase efficiency of the reaction. When PICs isolated from 
infected cells are subjected to high salt concentration, they lose a substantial amount of 
catalytic activity in vitro (Chen and Engelman, 1998; Farnet and Bushman, 1997; Lee 
and Craigie, 1994). However, when extracts from uninfected cells are added back to the 
reaction, catalytic integrase activity is restored. Such an assay has been used to identify 
host cell factors that might be important for efficient integration activity.  
 This method identified a number of factors that were able to reconstitute integration 
activity in vitro, including BAF (barrier to autointegration factor). In vitro MLV PICs 
often use their own DNA as an integration target, a process called autointegration. BAF is 
a cellular protein responsible for condensing DNA, and was found to block 
autointegration of the proviral DNA (Lee and Craigie, 1998; Suzuki and Craigie, 2002). 
Moreover, BAF was found to more generally inhibit integrase activity in in vitro assays. 
Making use of the same assay with HIV-1 PICs, HMGA was identified as a novel factor 
that stimulates integrase activity (Farnet and Bushman, 1997). However, the importance 




 Another method used to discover host cell factors that regulate integrase activity was 
to identify proteins that selectively bind the integrase protein. This was initially done 
making use of a yeast two-hybrid assay (Kalpana et al., 1994). This method uncovered 
the INI1 (integrase interactor 1) factor that has been demonstrated to stimulate HIV-1 
integrase activity in vitro. INI1 is a member of the SWI/SNF chromatin remodeling 
complex. It is believed to stimulate integration in vivo by stabilizing the HIV-1 PIC and 
maintaining integrase in a stable, active conformation (Suzuki et al., 2012).  
1.8 Different families of retroviruses have distinct integration site preferences 
  It was initially believed that integration sites were mandated by chromosome 
availability and that open chromatin would serve as a better integration substrate. 
However, all studied retroviruses exhibit distinct, non-random integration patterns 
(Demeulemeester et al., 2015; Derse et al., 2007; Mitchell et al., 2004; Schröder et al., 
2002; Wu et al., 2003).   
 Retroviruses show weak sequence preferences in vitro and in vivo but this is thought 
to play only a minor role in integration site selection (Pryciak and Varmus 1992). Further, 
retroviruses have differential preferences for integrating into nucleosomal DNA 
(Benleulmi et al., 2015; Pryciak and Varmus, 1992). HIV-1 and ALV preferentially 
integrate into nucleosome poor regions, while MLV and PFV prefer to integrate into 
stable and compact chromatin (Benleulmi et al., 2015). 
 For those retroviruses that do prefer a nucleosomal target, the DNA at SHL 
(superhelical location) +3.5 or SHL -3.5, where the major groove of the DNA is most 
exposed, is the primary target for integration, suggesting that DNA distortion might favor 




that DNA distortion outside of the nucleosome also supports integration (Bor et al., 1995; 
Müller and Varmus, 1994). While nucleosomes and other proteins that distort DNA may 
favor integration, proteins bound to the DNA can also inhibit integration by steric 
hindrance (Pryciak and Varmus, 1992). 
 Despite some cursory similarities, the integration patterns of different retroviruses 
vary significantly (Table 1.1). For instance, HIV-1 has a very strong preference for 
integrating into gene regions with as much as 75% of integrations falling into gene bodies 
(Schröder et al., 2002). Integration of HIV-1 specifically favors expressed genes as well 
as highly spliced genes, but integration across the gene body is fairly uniform (Mitchell et 
al., 2004; Singh et al., 2015).  
 Murine leukemia virus (MLV) on the other hand has a notable bias for integrating in 
the proximity of enhancer regions, CpG islands and transcription start sites (TSS) (Lafave 
et al., 2014; Mitchell et al., 2004; Wu et al., 2003). MLV was initially characterized to 
favor TSS and CpG islands with as much as 25% of integrations falling within 5 kb of 
TSS and 15% of integrations occurring within 1 kb of CpG islands. However, recent 
work suggests that the vast majority of MLV integration sites are located near 
nucleosomes with the H3K4me1 epigenetic mark, a hallmark of enhancer regions (De 
Ravin et al., 2014). 
 ALV possesses one of the most random integration patterns observed with only 
slight preferences for transcribed genes (Barr et al., 2005; Mitchell et al., 2004; Withers-
Ward et al., 1994). However, these previous studies used relatively little data to draw 
conclusions on ALV integration pattern. The studies were limited both by the number of 




annotated chicken genome and appropriate bioinformatics tools to correlate integrations 
with various genomic features. In Chapter 2, this thesis focuses on better characterizing 
the integration pattern of ALV in a high throughput manner. 
 Previous studies also largely focused on characterizing the integration pattern of 
ALV in human cells (Narezkina et al., 2004). In this work we characterize ALV 
integration in the natural host species. We specifically chose to work with DT40 cells, a 
chicken B-cell line derived from an ALV-induced bursal lymphoma (Winding et al. 
2001). Since ALV infection in vivo most commonly induces B-cell lymphomas, DT40 



















Genomic feature Random HIV-1 MLV ALV 
Within 5 kb of TSS 5% 6.9% 26.1% 8.4% 
Within 1 kb of CpG island 1% 0.2% 11.8% 3.1% 
Within genes 33% 77.9% 44.3% 42.0% 
 
Table 1.1: Summary of integration site preferences of studied retroviral genera. 
Shown are the frequencies with which integration is observed near transcription start sites 
(TSS), CpG islands and within gene bodies for HIV-1, MLV and ALV. For reference, the 
frequency with which you would expect integrations into these features if integration 
were entirely random is also shown. Data was adapted from Lewinski et al., 2006; 















1.9 Host factors regulate integration site selection 
 These unique integration site preferences of retroviruses have been shown to be the 
result of binding of the integrase proteins by distinct host cell factors. Retroelements have 
long been known to make use of cellular binding partners to direct integration into very 
specific locations throughout the host genome. In a seminal study, the yeast Ty5 
retroelement was shown to integrate preferentially into the heterochromatic telomere 
region and silent mating loci. This targeting activity was narrowed down to a 6 amino 
acid in the targeting domain of the Ty5 element integrase that was found to interact with 
the Sir4p protein, a structural component of silent chromatin (Gai and Voytas, 1998; Xie 
et al., 2001; Zou et al., 1996). Likewise, interaction between the TFIIIB complex and Ty3 
integrase targets integration of the element to within 2 nucleotides of RNA Pol III 
transcribed genes (Bridier-Nahmias et al., 2015). In both cases, the host cell factors 
bound both their natural DNA binding site as well as the integrase protein, serving to 
bring the two into close proximity, and thereby facilitate integration at these locations. 
 Host cell factors have likewise been found to be responsible for the observed 
integration site selection biases of different retroviral genera. These factors are similarly 
believed to act largely as bimodal tethers linking the PIC to distinct locations throughout 
the genome (Kvaratskhelia et al., 2014). The first such targeting factor identified was 
LEDGF (lens epithelial derived growth factor). LEDGF is a general transcriptional co-
activator that is found predominantly in gene regions. LEDGF was first found to 
stimulate HIV-1integrase catalytic activity in vitro, suggesting it may play a role in 
facilitating HIV-1 integration (Maertens et al., 2003). Upon knockdown of cellular 




hypothesis. Further, depletion of LEDGF caused a significant decrease in HIV-1 
integration in transcriptional units in vivo indicating a notable role for this cellular factor 
in targeting HIV-1 integration to genes (Ciuffi et al., 2005; Llano et al., 2006; Maertens 
et al., 2003). However, even in the absence of LEDGF, integration of HIV-1 into gene 
regions remained elevated above random. A second factor, CPSF6 (cleavage and 
polyadenylation specific factor 6) has also been shown to play a role in targeting HIV-1 
integration to gene-tropic regions of the genome (Sowd et al., 2016). Interestingly, 
CPSF6 was found to bind the HIV-1 CA protein rather than the IN protein indicating that 
conventional IN focused studies may be limiting. 
 Host cell factors that regulate integration of other retroviral families, such as the 
gammaretroviruses, have also been recently discovered. The BET (bromodomain and 
extraterminal) family of proteins was found to play a significant role in promoting and 
targeting MLV integration (De Rijck et al., 2013; Sharma et al., 2013). The BET proteins 
were identified as binding partners of MLV IN using an affinity chromatography 
approach coupled with mass spectrometry. The BET proteins are a class of bromodomain 
containing proteins that bind acetylated lysines of H3 and H4 tails, a common epigenetic 
modification found at transcription start sites (Florence and Faller, 2001). Inhibiting the 
BET proteins ability to bind chromatin significantly decreased MLV integration 
efficiency as well as targeting of integration to transcription start sites, suggesting that the 
BET proteins likely also act as bimodal tethers linking the PIC to specific genomic 
locations (Sharma et al., 2013). 
The cellular serine/threonine protein phosphatase 2A (PP2A) was recently identified 




bind IN directly and stimulate in vitro integration activity (Maertens, 2016). However, 
PP2A does not bind chromatin and thus does not likely act as a bimodal tether as 
hypothesized for LEDGF and BET. The importance of PP2A in regulating deltaretroviral 
integration in vivo also remains unclear. 
 Due to the pervasive utilization of host cell factors to regulate integration site 
selection amongst retrotransposons and retroviruses alike, it seems likely that ALV 
utilizes a similar mechanism to mediate integration pattern. However, the factors 
responsible for the more random integration pattern of ALV were previously unknown. 
Chapters 3 and 4 of this thesis elucidate the host cell factors that aid ALV integration 
efficiency as well as target integration sites. 
1.10 Consequences of integration 
 That integration of the viral genome is an obligate part of the retroviral life cycle 
makes retroviruses uniquely well suited for use in gene therapy. The ability to 
integrate into the host genome is an attribute ideal for stable, long-term transgene 
expression. The first human gene therapy trials over 25 years ago attempted to treat 
severe combined immunodeficiency syndrome (SCID) using a retroviral vector system to 
deliver a wild type copy of the causative mutated gene (Dornburg, 2003; Rans and 
England, 2009). However, throughout these early studies, patients remained on drug 
therapy and thus, the benefit of the gene therapy treatment alone was ambiguous. In 
2000, two landmark clinical SCID trials in France and England were incredibly 
successful, with over 85% of patients being cured (Cavazzana-Calvo et al., 2000; Hacein-




materialized. However, following treatment, nearly a quarter of the patients in the trials 
developed T-cell leukemia (Hacein-Bey-Abina et al., 2008; Howe et al., 2008).  
 Retroviruses had been known to be associated with cancer in the past, most notably, 
Rous Sarcoma Virus, or RSV in chickens (Rous, 1910). Research on RSV, a derivative of 
ALV, had revealed that with establishment of an integrated viral genome, or provirus, 
retroviral elements are produced that flank the genome. These so-called long terminal 
repeats (LTRs) contain strong enhancer and promoter elements that attract host proteins 
to drive the expression of viral proteins (Gowda et al., 1988; Laimins et al., 1984).  If 
viral integrations happen near host genes, the strong viral regulatory elements can also 
affect the expression of these genes (Hayward et al., 1981). In addition to the positive 
regulatory elements, proviral integration also inserts splice donor and acceptor sites that 
can lead to production of a host-viral fusion protein with altered regulation or function 
(Neel et al., 1981).  
 Sequencing of leukemic cells from afflicted gene therapy patients identified 
retroviral vector integrations near proto-oncogenes, most notably LMO2 (McCormack 
and Rabbitts, 2004). This highlights one of the most serious risks with using retroviral 
vectors – that integration into the host genome is uncontrolled.  
 Human gene therapy trials to date have largely focused on the use of MLV and HIV-
1 based vectors for gene delivery. While both viral vectors possess broad tropism and 
good expression in human cells, they also possess harmful integration patterns with 
strong preferences for integrating in and around regulatory regions and active gene 
regions respectively. Thus, there is a significant risk of deleterious insertional 




(ALV) however, may make a safer alternative due to its relatively random integration 
pattern. Therefore, understanding the mechanism by which retroviral integration is 
naturally targeted to specific locations throughout the genome in general may aid in the 
development of safer retroviral gene therapy vectors. 
 While insertional mutagenesis by integration of the retroviral genome into the host 
cell genome poses a substantial risk in human gene therapy, this process can also be used 
as a tool to identify novel gene players involved in tumorigenesis. 
1.11 ALV as an insertional mutagenesis tool  
ALV induces tumors in chickens by insertional mutagenesis (Beemon and 
Rosenberg, 2012). ALV typically induces B-cell lymphomas, but can also induce 
erythroblastomas, hemangiomas, and myeloid tumors (Beemon and Rosenberg, 2012; 
Justice and Beemon, 2013; Justice et al., 2015a). As mentioned previously, proviral 
integration can lead to the misregulation of nearby host genes or the production of altered 
viral fusion proteins which can subsequently lead to tumorigenesis. Viral integrations can 
perturb host genes by various mechanisms (Figure 1.3). The first such described 
mechanism was promoter insertion. Both the 5’ and 3’ LTRs contain strong promoter and 
enhancer elements and if the virus integrates in the same transcriptional orientation as a 
nearby gene, the strong viral promoter from either the 5’ or 3’ LTR can be utilized to 
drive high levels of expression of the nearby gene, If the 5’ LTR is used, the viral splice 
donor often splices into downstream exons of adjacent genes (Figure 1.3A). If the 3' LTR 
is used instead, transcription proceeds through the viral poly(A) site in a process called 
readthrough (Figure 1B; Hayward et al., 1981). This can lead to the overexpression of 




nearby gene expression when the provirus is integrated in either orientation upstream or 
downstream of the host gene (Figure 1.3C; Yang et al., 2007a).   
Proviral integration can also cause the expression of altered protein products. This 
can occur when transcription initiates from the promoter in the 5’ LTR and uses the viral 
splice donor site to splice to exons of downstream genes (Figure 1.3D). Another 
mechanism by which integration can generate altered protein products is when viral 
transcription reads through into adjacent cellular sequences. Both of these mechanisms 
drive the expression of viral fusion transcripts that can potentially lead to the loss of 
functional or regulatory domains and thereby alter protein function (Coffin et al., 1997). 
In theory the integration of a provirus into the gene body can also abrogate expression of 
















Figure 1.3: Mechanisms of retroviral insertional mutagenesis. (A) Activation of host 
gene expression by viral promoter insertion. The LTRs of the integrated provirus contain 
strong promoter elements that can drive the overexpression of nearby host genes. (B) 
Viral promoter can splice into downstream exons of a nearby gene to drive the expression 
of splice variants. (C) Viral enhancer elements contained in the LTRs can also promote 
nearby gene expression. (D) If the virus integrates within a gene it can lead to the 




















 While there is an initial inherent integration bias, in vivo selective forces shape the 
final distribution of integration sites in the host cell genome. For instance, if a provirus 
integrates into or near an oncogenic or pro-survival gene, cells with this integration will 
become clonally expanded and form a tumor. By mapping integration sites in tumors, 
genes that harbor clonally expanded or recurrent integrations can be identified. This 
process of integration and selection allows us to find novel genes that may be involved in 
tumorigenesis. Previous studies have shown common integration sites in ALV-induced 
lymphomas in MYC, MYB, BIC (miR 155 precursor), and TERT genes (Hayward, Neel, 
and Astrin 1981; Baba and Humphries 1986; Clurman and Hayward 1989; Yang et al. 
2007a; Justice, Morgan, and Beemon 2015a).  
Initial studies mapping integrations in ALV-induced B-cell lymphomas found that 
nearly all (~80%) analyzed tumors possessed integrations upstream  of MYC transcription 
start site (Hayward et al., 1981a; Neel et al., 1981). Integrations led to the production of a 
fusion transcript that contained a full length copy of the MYC RNA by a mechanism 
consistent with promoter insertion. Tumors containing MYC integrations were induced 
by infecting chickens 2-7 days post hatching with ALV. Infections produced long 
latency, late onset B-cell lymphomas 4-6 months post infection. Later, integrations in 
BIC, the precursor to the noncoding mir-155, were found to co-occur relatively frequently 
with c-myc activation and play a role in later stages of lymphomagenesis (Clurman and 
Hayward, 1989; Tam et al., 1997).  
Further work from the same lab showed that infection of 10-day-old chicken 
embryos with a recombinant ALV strain, deemed EU-8, resulted in rapid onset B-cell 




the MYB locus (Kanter et al., 1988). Integrations were detected predominantly upstream 
of the AUG initiation codon in intron 1 and generated truncated viral fusion transcripts. 
The EU-8 viral strain possessed a deletion in a viral sequence that negative regulated 
splicing (NRS) allowing for increased efficiency of viral readthrough and viral splicing to 
downstream genes (Smith et al., 1997) 
Our lab performed a similar insertional mutagenesis screen making use of a 
similar ALV variant, LR-9, with a mutation in the NRS, which induced rapid-onset B-cell 
lymphomas. These tumors were previously analyzed by lower-throughput methods 
(Polony et al., 2003; Yang et al., 2007a). The TERT promoter was identified as a common 
site of integration in these tumors with all integrations occurring between approximately 
200 and 2500 bp upstream of the TERT transcriptional orientation. Interestingly, all 
identified clonally expanded integrations were in the opposite orientation of TERT 
transcription (Yang et al., 2007a). At the time, the integrations were thought to activate 
TERT expression in these tumors via insertion of the viral enhancer.  
Our insertional mutagenesis screen, partially described here, improves upon the 
aforementioned studies by sequencing integration sites in tumors in a high throughput 
manner. Sequencing of a large number of tumors allows us to identify recurrent 
integration sites that are common to multiple independent tumors. Further, the use of 
random sonication to fragment the genomic DNA in the sequencing library preparation 
allow us to also quantify unique breakpoints (Firouzi et al., 2014; Justice et al., 2015a, 
2015b). The larger number of breakpoints, the higher the abundance of a specific 




Both clonal expansion and recurrent integration into a region would implicate a nearby 
gene in the formation of the tumor. 
This study identified a number of expected targets such as MYB and MYC. The 
most clonally expanded integration site was the TERT promoter with an average of 19 
breakpoints per integration, in agreement with the previous preliminary characterization 
of these tumors by Yang, et. al. (Justice et al., 2015b; Yang et al., 2007a) Again, 
consistent with previous reports from the lab, the majority of integrations were in the 
TERT promoter region in the opposite transcriptional orientation of TERT. In Chapter 6 
of this thesis, I follow up on the role of these integrations in the TERT promoter in 
tumorigenesis.  
Other common integration sites that exhibited clonal expansion were the 
phosphatase genes, CTDSPL and CTDSPL2. CTDSPL has previously been linked to 
cancer as a tumor suppressor gene. Relatively little was known about the function of 
CTDSPL2. In Chapter 5, I explore how integrations in these genes affects expression and 
how this subsequently leads to the development of cancer. 
The vast majority of putative oncogenes discovered in early mutagenesis screens 
have proven to be important players in human tumorigenesis indicating that the chicken 
is a valid model for studying cancer. By identifying sites of ALV integration in B-cell 
lymphomas we are able to provide insights into the molecular underpinnings of initiation, 



































Integration of the proviral genome into the host cell genome is an obligate part of 
the retroviral life cycle. Integration however is not a random process. Different 
retroviruses display distinct integration site preferences. While the integration patterns of 
HIV-1 and MLV have been well characterized, the pattern of ALV has only been studied 
with relatively few data. In this study we make use of high throughput sequencing to 
identify more than nine thousand ALV integration sites in the chicken genome. This is 
more than 10-fold the amount of data that has been analyzed in past studies. We also 
make use of new bioinformatics tool sets to correlate integrations with specific genomic 
annotations, as well as gene expression, splicing, gene length, CpG islands, and 
transcription start sites. We observe that ALV integration deviates slightly from what 
would be expected by random chance. However, we do not observe any strong 
integration biases such as that which is seen with MLV and HIV-1. Our data improves 
upon previously existing studies and sets the stage for further analysis of the mechanism 













Integration into the host cell genome is a defining feature of the retroviral life cycle. 
While it is believe that the majority of the host cell genome is available for integration, 
the process is not random (Engelman, 1994). There are seven known genera of 
retroviruses and each has unique integration site biases. For instance, lentiviruses such as 
human immunodeficiency virus type-1 (HIV-1) have a very strong bias for integrating 
into actively transcribed genes, with some reports suggesting that more than ¾ of all 
HIV-1 integrations are in transcribed gene units (Lewinski et al., 2006; Mitchell et al., 
2004; Schröder et al., 2002). The level of transcription is also important in dictating 
integration events, with integration favored in more highly expressed genes (Mitchell et. 
al. 2004). More recently, HIV-1 was also shown to have a preference for integrating into 
highly spliced genes (Singh et al., 2015). The deltaretroviral genus, which includes 
HTLV-1, also displays a bias for integration into transcriptionally active regions (Derse 
et al., 2007). Murine leukemia virus (MLV), of the gammaretrovirus family, prefers to 
integrate near transcription start sites, CpG islands and enhancer regions (Lafave et al., 
2014; Mitchell et al., 2004; De Ravin et al., 2014; Wu et al., 2003). In contrast to the 
aforementioned retroviral genera, integration of spumaviruses such as prototype foamy 
virus (PFV) is highly disfavored in or near genes or transcribed regions (Trobridge et al., 
2006). The most randomly integrating retroviruses are the alpha- and betaretroviral 
genera which include avian leukosis virus (ALV) and mouse mammary tumor virus 
(MMTV) respectively (Barr et al., 2005; Faschinger et al., 2008; Mitchell et al., 2004; 




ALV integration has been interrogated in multiple studies that have found the 
integration pattern to be relatively random. The first such study, Mitchell et. al. found 
that ALV integration is not significantly favored at the transcription start site, does not 
correlate with gene expression, and is modestly enriched near CpG islands (Mitchell et 
al., 2004). This study analyzed 469 integration sites in human HEK293T cells. A study 
from the same year, Narezkina et. al., analyzed an even smaller data set, 226 integrations, 
also in the human genome and found that transcription units were favored integration 
targets and that there was a preference for actively expressed genes though extent of 
expression had no effect on integration frequency (Narezkina et al., 2004). Barr et. al. 
looked at integration preferences of ALV in the chicken genome and similarly found a 
slight preference for actively transcribed genes (Barr et al., 2005).  
In each of these studies integration sites were cloned and sequenced using linker 
mediated inverse PCR in a low throughput manner. Thus, the maximum number of sites 
looked at in any one study was approximately 800. Further, gene expression data used to 
correlate integration with expression level was obtained using microarrays and did not 
include all genes. In our study, we have used high throughput sequencing to identify and 
map more than 9,000 integration sites, a significant improvement upon previous studies. 
We also have obtained RNA-seq data with expression data for all genes. Bioinformatics 
toolsets have also improved and allow us to correlate all integrations with various 
features such as transcription start sites, CpG islands, gene length, splicing and more.  
We find that similar to previous reports ALV does prefer to integrate into expressed 
genes relative to random but that level of expression does not enhance integration. We 




disagreement with some previous data we find that there is an enrichment of integration 
around CpG islands, though this preference is not comparable to that observed for MLV. 
We also see that there is a slight preference for integration flanking transcription start 
sites, which has not been seen before. Lastly we observe that there is a preference for 























ALV integration is significantly enriched into expressed genes 
 Previous works looking at the integration pattern of ALV in cell culture were 
done with a much smaller number of integrations and a less well-annotated genome. In 
order to better characterize the integration pattern of ALV, we performed high throughput 
sequencing of integration sites in DT40 cells, a chicken B-cell lymphoma derived line 
(Winding et. al. 2001). Importantly, we allowed infection to proceed for only 24 hours 
and thus there should not be a significant amount of selection for integration sites post 
integration. We recovered 9,210 unique integration sites. We generated a random set of 
integrations by generating 350,000 random reads (RandomBed) and mapping them back 
to the chicken genome through the same bioinformatics pipeline used to analyze our 
experimental DT40 integration data. All subsequent analyses were performed on the 
random and experimental sets of reads in parallel. The vast majority of integrations 
(91%) had only one breakpoint indicating that there was very little clonal expansion of 
integration sites at 24 hours post infection. The lack of clonal expansion indicates a lack 
of selection and thus an unbiased integration profile. 
After integration sites were successfully mapped to the galGal4 RefSeq genome 
using BowTie, they were analyzed using HOMER bioinformatics tools to assign a 
specific annotation to each site (Table 2.1). ALV integrations were observed to be near 
random for most genomic features analyzed. Our data is also consistent with previous 
reports of ALV integration pattern. The most notable deviation from random is the 
observed preference of ALV to integrate into RefSeq genes. We observed that 




random integrations. There also appears to be a 15-fold enrichment of ALV integrations 
into satellite sequences as compared to random. Lastly, we observe an approximately 2-
fold enrichment of ALV integration in the proximity of CpG islands. Integration pattern 
did not differ significantly in chick embryo fibroblasts indicating that pattern is likely not 






















Annotation Random DT40 
3UTR 0.4 0.6 
miRNA 0.0 0 
ncRNA 0.0 0 
TSS 
(within 5kb) 5.9 10.1 
TTS 0.7 1 
LINE 6.8 10.7 
SINE 0.2 0.02 
tRNA 0.0 0 
Exon 0.6 1 
Intron 12.6 13.8 
RefSeq genes 27.0 40.4 
Promoter 0.6 0.56 
5UTR 0.0 0.05 
CpG-Island 1.1 2.5 
Low_complexity 0.6 0.3 
LTR 1.6 3.1 
Simple_repeat 0.6 1.5 
Unknown 0.0 0.07 
Satellite 0.3 4.5 
 
 Table 2.1: ALV integration into selected genomic annotations. Using HOMER 
bioinformatics tools, we calculated the percent of integrations that fall within each of the 
listed genome annotations in the galGal4 reference genome. We simulated a matched 










To further investigate the preference for ALV to integrate into genes, we asked 
whether ALV had a bias for integrating into expressed or non-expressed genes. DT40 
expression levels were gathered from publically available RNA-seq data (SRR912956). 
Integrations were called to the nearest RefSeq gene and correlated with gene expression 
as measured by FPKM (fragments per kilobase per million reads; Figure 2.1). We 
observed a slight but highly significant depletion of integrations in or near non-expressed 
genes (FPKM of 0). In DT40 cells, a random integration pattern would result in 
approximately 17% of integrations into non-expressed genes, whereas for ALV 
integration we observe about 12% of integrations falling into this bin indicating that ALV 
has a slight bias for integrating into expressed genes, however, the level of expression did 
not significantly affect the extent of integration. 
Because our pipeline ascribes integrations to the nearest gene, in some instances 
integrations can be many hundreds of kilobases away from a transcriptional unit. To 
address this, we repeated the above-described analysis with integrations that fall within 5 
kb of a transcriptional unit. We observed a very similar distribution of integrations 
















Figure 2.1: ALV integrates preferentially into expressed genes but does not 
discriminate based on expression level. We obtained DT40 transcriptome data from 
publically available RNA-seq data. We then generated bins of expression level and 
correlated integrations with the expression level of the nearest gene. Expression was 
quantified as FPKM (fragments per kilobase per millions reads). This analysis was also 
done on a matched random control set of integration sites. DT40 data is shown in red and 








ALV has a slight preference for integration around the transcription start site of genes. 
 We next looked at bias for integration in the proximity of transcription start sites 
(TSS).  Previous ALV integration data in cell culture revealed a preference for 
transcribed genes, but no significant preference for the TSS specifically. In contrast, 
previous work from our lab has shown that there is a significant bias for integration 
around the TSS in ALV-induced tumor samples (Justice et. al. 2015), but it was unclear if 
this was impacted by selection in vivo. To answer this question, we again made use of 
HOMER bioinformatics tools to determine the distance of the site of integration to the 
nearest transcription start site.  
We observed that ALV integration is enriched around the transcription start site, 
most notably in the 10 kb region flanking the TSS (Figure 2.2). Interestingly, in the 
immediate vicinity of the transcription start site (within 1 kb), there is a notable decrease 
in integration relative to random. This trend is consistent with what was previously 
observed by our lab in vivo chicken tumors, but the enrichment is much less pronounced 
in our cell culture system. This indicates that there is some initial bias for integrating into 














Figure 2.2: ALV exhibits a slight bias for integration near transcription start sites. 
Distance between the site of integration and the nearest TSS was calculated using 
HOMER bioinformatics tools for both DT40 as well as a matched random control. ALV 
integrations into DT40 cells are shown in blue, while the random control set is shown in 
red. Integration frequency as a function of distance from the TSS is shown in the (A) 100 







ALV has some preference for integrating near the 5’ end of genes 
 Other retroviruses have been shown to exhibit preferences for integration within 
the gene body. For instance, MLV and HIV exhibits a strong bias for integrating into the 
5’ end of gene bodies (X. Wu et al. 2003, Bushman et. al. 2005). Of ALV integrations 
that fall into the gene body, we asked if there was a preference for position within the 
gene. We normalized for gene length and set up 20 equal bins throughout the gene body 
each corresponding to 5% of the gene length. We then determined what percent of 
integrations fell within each bin (Figure 2.3). Interestingly, in the first 15% of the gene 
body, ALV integrations into DT40s seem to be slightly enriched relative to the random 














Figure 2.3: ALV integration exhibits a slight preference for integrating near the 5’ 
end of genes. Integrations that fell within the body of a gene were mapped to 1 of 20 bins 
based on where the fell in the gene body. Shown are the percent of integrations with 
respect to the proportion of the gene length. Data for integrations in DT40 are shown in 
















ALV integration is biased for spliced genes. 
 HIV has been shown to have a preference for integrating into highly spliced genes 
(Singh et al., 2015). This is a feature that has never been analyzed for ALV integration. 
Thus, we correlated percent of total ALV integration with the extent of splicing of the 
nearest gene (Figure 2.4). There was a notable depletion of integrations into unspliced 
genes. If integration were random, approximately 12% of the integrations would fall into 
unspliced genes. However, in DT40 cells, we observed that on average only 2% of 
integrations fell into unspliced genes. However, there did not appear to be any additional 














Figure 2.4: ALV has a preference for integrating into spliced genes. Integrations were 
correlated to the number of exons of the nearest RefSeq gene in the galGal4 chicken 
genome assembly. This analysis was performed in parallel for ALV integrations in DT40 















ALV prefers to integrate into shorter rather than longer genes 
 We hypothesized that perhaps the preference for integrating into spliced genes 
could really be a preference for integrating into larger genes. Thus, we correlated 
integrations to the total length of the nearest gene (Figure 2.5). We observed that contrary 
to the preference for integrating into spliced genes, ALV actually tends to integrate into 















Figure 2.5: ALV prefers to integrate into smaller genes than would be expected by 
random chance. The length of the most proximal gene to the site of integration was 
analyzed. Shown is the percent integrations that occur with respect to total gene length. 
ALV integration data in DT40 cells is shown in red and a matched random control is 














ALV exhibits a bias for integration in the proximity of CpG islands 
 From the initial HOMER analysis of integration sites there was an approximate 2-
fold enrichment of integrations into CpG islands as compared to a matched random 
control (Table 2.1). To verify this and further investigate, we calculated integrations in 
the proximity of CpG islands. The percent of integrations in the 1 or 5 kb region flanking 
CpG islands was calculated for ALV integrations in DT40s and a random set of 
integrations (Figure 2.6). Within 1 kb of CpG islands, we observed approximately 8% of 
ALV integrations as compared to 5% of integrations in the random set of integrations. 
The enrichment was more notable when we looked at the 5 kb region flanking CpG 
islands. In this region we observed approximately 20% of random integrations as 
opposed to more than 35% of ALV integrations in DT40 cells. Preference for integration 
into CpG islands is strongly associated with MLV integration (Wu et. al. 2003) but we 
report here that ALV also has a fairly strong preference for integrating in the vicinity of 










Figure 2.6: ALV has a preference for integrating near CpG islands. CpG island 
locations were extracted from the galGal4 reference genome. BedWindow was used to 
calculate the overlap of the integration sites with CpG islands with a 1 or 5 kb range 
flanking each CpG island. Shown is the percent integrations that fall in the 1 or 5 kb 
surrounding CpG islands. Percent of ALV integrations in DT40 cells in each category are 













There is a slight sequence preference at the site of ALV integration. 
 As has been previously observed in human and chicken cells, there is a slight 
sequence preference at the site of ALV integration. There is a strong preference for a T -3 
nucleotides from the integration site as well as a preference for G at +1 and A at +9. The 
consensus sequence is palindromic and appears to be more symmetrical than has been 












Figure 2.7: ALV has a modest sequence preference at the site of integration. 
Nucleotide frequencies flanking the site of integration were calculated using HOMER 
bioinformatics tools. Shown is the frequency with which each nucleotide appears at a 
given position flanking the integration site. The black line indicates the site of 
integration. The boxed nucleotide positions correspond to the sequence duplicated in the 










 The data reported here are largely consistent with previously published data. For 
instance, we find a preference for integration into genes relative to random in agreement 
with Narezkina et. al. and Barr et. al. . We also find that there is a preference for 
transcribed genes but that level of transcription does not significantly affect extent of 
integration consistent with Narezkina et. al.  However, unlike previous studies, we 
observed a preference for integration around the transcription start site of genes as well as 
in the proximity of CpG islands. In addition we correlated integration with gene splicing, 
gene length, and gene body, all attributes that had not been previously characterized. We 
see a preference for integration into short genes, spliced genes and the 5’ end of genes. 
Our data may differ from previous studies largely due to sample size, a better-annotated 
genome and better bioinformatics tools. 
 While DT40 cells serve as the parental “wild-type” condition in our studies in the 
following chapters, they were actually originally isolated from a bursal lymphoma. Thus, 
it was unclear whether the integration pattern observed in DT40 cells would be more 
similar to that observed in primary cell lines or tumors. A parallel study in the lab 
analyzed integration pattern of ALV in primary chicken embryo fibroblasts in culture as 
well as in chicken tumors (Malhotra et al., 2017). It was found that the largest 
discrepancy between integration pattern in primary cells and tumors was in the proximity 
of transcription start sites and CpG islands. In tumors, integration was more highly 
preferred near the transcription start site and less preferred in the proximity of CpG 
islands as compared to the integration pattern in primary cells. The integration pattern 




embryo fibroblasts. This indicates that the discrepancies in integration pattern seen in 
tumors are the result of selection over time. Thus, DT40 cells are a relevant model in 
which to study wild type ALV integration pattern. 
 While we do see slight integration biases, ALV integration is still significantly 
more random than either MLV or HIV-1 integration. For instance, we see approximately 
40% of ALV integration into genes as compared to 27% for a matched random control. 
While this is certainly enriched above random, it is not as strong of a preference as HIV-
1. Nearly 75% of HIV-1 integration have been reported to fall within transcribed genes 
(Mitchell et al., 2004; Schröder et al., 2002). Similarly, depending on the study, an 
average of about 12% of MLV integrations fall within 1 kb of CpG islands, compared to 
5% expected by random chance. We observe only roughly 7% of ALV integration in this 
same region, an increase above random, but not a strong bias as observed for MLV 
(Mitchell et al., 2004). We see about 10% of total ALV integrations fall within 5 kb of a 
transcription start site compared to only about 5% of random integrations. However, 
more than 25% of MLV integrations fall in that same category (Wu et al., 2003). Thus, 
while ALV does deviate from a random integration pattern, there are no striking 
integration biases. 
It was originally thought that integration might be influenced by chromatin 
accessibility. However, the distinct integration site preferences of different retroviruses 
make it unlikely that this is the sole mechanism determining integration site selection. 
Early studies on yeast Ty retrotransposons, which are similar to retroviruses, discovered 
that integration is targeted to very specific chromosomal locations by tethering of the 




For instance, binding of the integrase protein to the Sir4 protein targets the Ty5 
transposon to heterochromatin (Dai et al., 2007). This led to screens looking for similar 
host cell factors that might be responsible for retroviral targeting. Such studies have 
identified LEDGF and CPSF6 as targeting factors of HIV-1 and the BET proteins as 
targeting factors for MLV integration (Maertens et al., 2003; Sharma et al., 2013; Sowd 
et al., 2016). 
The majority of human gene therapy trials to date have utilized HIV-1- and MLV-
based vectors, which due to their biased integration into genes and regulatory regions 
have a high incidence of insertional mutagenesis (Hacein-Bey-Abina et al., 2008; Howe 
et al., 2008). The more random integration pattern of ALV integration may reduce the 
risk of deleterious integration (Suerth et al., 2014). Understanding how ALV integration 



























































Adapted from:  
Winans, S., Larue, R.C., Abraham, C.M., Shkriabai, N., Skopp, A., Winkler. D., 
Kvaratskhelia, M., and Beemon, K.L. (2017) The FACT complex promotes avian 











 All retroviruses need to integrate a DNA copy of their genome into the host 
chromatin. Cellular proteins regulating and targeting lentiviral and gammaretroviral 
integration in infected cells have been discovered, but the factors that mediate 
alpharetroviral avian leukosis virus (ALV) integration are unknown. Here, we have 
identified the FACT protein complex, which consists of SSRP1 and Spt16, as a principal 
cellular binding partner of ALV integrase. Biochemical experiments with purified 
recombinant proteins show that SSRP1 and Spt16 are able to individually bind ALV IN, 
but only the FACT complex effectively stimulates ALV integration activity in vitro. 
Likewise, in infected cells, the FACT complex promotes ALV integration activity with 
proviral integration frequency varying directly with cellular expression levels of the 
FACT complex. An increase in 2-LTR circles in the depleted FACT complex cell line 
indicates that this complex regulates the ALV life cycle at the level of integration. This 
regulation is shown to be specific to ALV, as disruption of the FACT complex did not 
inhibit either lentiviral or gammaretroviral integration in infected cells. Integration 
pattern was subtly but significantly affected by knockdown of the FACT complex 











Retroviral integration into the host genome is not random and varies dramatically 
across genera. Lentiviral HIV-1 has been shown to exhibit strong integration site 
preferences within active gene units, whereas gammaretroviral MLV exhibits a strong 
preference for enhancers and transcription start sites (Lewinski et al., 2006; Schröder et 
al., 2002; Wu et al., 2003).  These biases have been attributed to interaction of IN in the 
context of the pre-integration complex with their cognate host cell factors (Craigie and 
Bushman, 2014; Debyser et al., 2015; Kvaratskhelia et al., 2014). For example, cellular 
chromatin associated protein lens epithelial-derived growth factor (LEDGF/p75) interacts 
with HIV-1 IN and directs lentiviral integration into actively transcribed genes (Ciuffi et 
al., 2005; Llano et al., 2006; Maertens et al., 2003). Similarly, BET (bromodomain and 
extraterminal domain) proteins have been shown to interact with MLV IN and target 
MLV integration to transcription start sites, enhancers and gene regulatory regions (Aiyer 
et al., 2014; El Ashkar et al., 2014; Gupta et al., 2013; De Rijck et al., 2013; Sharma et 
al., 2013). These host cell factors bind their cognate viral IN and select histone marks to 
act as a bimodal tether to recruit the pre-integration complex to specific genomic regions 
surrounding the host factor binding sites (Craigie and Bushman, 2014; Debyser et al., 
2015; Eidahl et al., 2013; Kvaratskhelia et al., 2014; Larue et al., 2014). In addition to 
targeting integration events to specific genomic features, these factors also serve to 
significantly enhance integration efficiencies (Llano et al., 2006; Sharma et al., 2013; 
Shun et al., 2007).  
A recent study has identified cellular serine/threonine protein phosphatase 2A 




type 1 and 2 and bovine leukemia virus) INs (Maertens, 2016). Furthermore, the B’ 
subunit of PP2A has been shown to bind and stimulate concerted integration of 
deltaretroviral INs in vitro (Maertens, 2016). However, unlike LEDGF/p75 and BET 
proteins, PP2A does not directly engage chromatin, and it remains to be seen whether this 
cellular protein can modulate delta-retroviral integration in infected cells. 
 Alpharetroviruses such as ALV exhibit a distinct integration pattern with 
seemingly random distribution of integration sites throughout chromatin and with only a 
slight preference for integrating into gene regions (Barr et al., 2005; Mitchell et al., 2004; 
Narezkina et al., 2004; Withers-Ward et al., 1994). To understand how ALV integration 
is regulated by host cellular factors, we have performed affinity capture of the ALV IN 
protein followed by mass spectrometry (MS)-based proteomics experiments to identify 
protein binding partners. Using this approach we identified structure specific recognition 
protein 1 (SSRP1) and suppressor of Ty 16 (Spt16), the components of the heterodimeric 
FACT (facilitates chromatin transcription) complex (Orphanides et al., 1999), as the top 
protein hits that specifically bound to ALV but not HIV-1 IN. 
The FACT complex is a highly conserved general histone chaperone protein that 
is essential for transcription and DNA replication (Abe et al., 2011; Belotserkovskaya and 
Reinberg, 2004; Orphanides et al., 1998). The complex has also been shown to play 
important roles in DNA damage responses, centromere deposition, recombination and 
DNA methylation (Ikeda et al., 2011; Kumari et al., 2009; Okada et al., 2009; Oliveira et 
al., 2014). The FACT complex is thought to destabilize the histone octamer, providing 




and Luger, 2011). The complex is also important for reassembling nucleosomes after 
polymerases have moved through the DNA to establish new chromatin (Formosa 2012). 
In this report, we show that both components of the FACT complex, SSRP1 and 
Spt16, can individually bind ALV IN. Furthermore, we show that the C-terminal domain 
(CTD) of ALV IN is essential for the interaction with the FACT complex. In vitro 
integration activity assays reveal that the FACT complex, rather than its individual 
components, specifically stimulates ALV but not HIV-1 IN activity. Our findings also 
indicate that the FACT complex regulates ALV integration in infected cells as the 
frequency of ALV proviral integration is directly correlated with the abundance of the 
FACT complex. The decrease in proviral integration when the FACT complex was 
depleted was accompanied by an increase in 2-LTR circles, indicating that the FACT 
complex stimulates the integration step of the viral life cycle. Moreover, we show that the 
FACT complex specifically promotes ALV integration, as cells with depletion of the 
FACT complex had no inhibitory effect on either HIV-1 or MLV integration efficiencies. 
High throughput sequencing of viral integration sites in the presence and absence of the 
FACT complex reveal subtle but significant differences in pattern of integration 
suggesting that the FACT complex may also be playing a role in targeting ALV 










The FACT complex specifically interacts with and stimulates catalytic activity of ALV IN 
To identify host cell factors that bind ALV IN, we performed affinity capture 
coupled with MS analysis using recombinant His-tagged ALV and HIV-1 INs as baits 
and nuclear extracts of uninfected chicken DT40 and human Sup-T1 cells. Unique hits 
that were reproducible in both cell lines were identified through semiquantitative analysis 
of peptide spectral counts. This revealed SSRP1 and Spt16, the components of the FACT 
complex, to be main binding partners of ALV IN (Figure 3.1A). Using a taxonomy of 
“Homo sapiens” (human) allowed us to identify these proteins from Sup-T1 cells. 
However, since the MASCOT search engine does not contain a chicken taxonomy, we 
used higher order classification of “bony vertebrates” for analyzing DT40 proteins. In 
these samples Spt16 (which is not annotated in chicken cells) was identified due to the 
high homology with its human counterpart. The confidence in the correct identification of 
Spt16 in DT40 cells is high due to identification of 16 unique peptides and 18% coverage 
of the protein (Figure 3.1B). SSRP1 is functionally annotated in both species and was 
identified by MASCOT as chicken or human origin depending on the cell type. No 
interacting peptides from either of these FACT complex proteins were detected in parallel 
HIV-1 IN pull-down fractions.  In contrast, as expected LEDGF/p75 peptides were 
detected in HIV-1 but not with ALV IN pull-downs (Figure 3.1A).  
Other candidate factors that were enriched in the ALV IN pulldown fraction 






Figure 3.1: MS-based proteomics analysis of cellular binding partners of ALV and 
HIV-1 INs. Two independent experiments with Sup-T1 (human) and DT40 (chicken) 
cells were performed. (A) Shown is the list of top unique protein hits (compiled from 
both cell lines) from nuclear extracts of DT40 or Sup-T1 cells. Semiquantitative values of 
peptide spectral counts for each identified protein are indicated. ND: no peptides from the 
indicated protein were detected. (B) Summary of identified peptides sequences from 
SSRP1 and Spt16, which are indicated in bold and highlighted in yellow. Total spectral 
counts for SSRP1 peptides were 85 and 32 in SupT1 and DT40 cells respectively, 
yielding 36% (254 out of 709) and 19% (192 out of 1006) amino acid coverage.  In sharp 
contrast, no SSRP1 peptides were detected in parallel experiments with HIV-1 IN. Total 
spectral counts for Spt16 peptides in SupT1 and DT40 cells were 103 and 39, yielding 
33% and 18% (341 out of 1047) amino acid coverage, respectively. Spt16 in DT40 cells 
was identified based on its homology with the corresponding human gene. In sharp 
contrast no Spt16 peptides were detected in parallel experiments with HIV-1 IN.  










  Cells 
  DT40 Sup-T1 
Candidate proteins ALV IN HIV-1 IN ALV IN HIV-1 IN 
Fact complex subunit Spt16 39 ND 103 ND 
Fact complex subunit SSRP1 32 ND 85 ND 











Table 3.1: Host cell factors that bind ALV integrase protein. Top host cell factors that 
were enriched in the ALV IN pulldown fraction versus the HIV-1 IN pulldown fraction 
are shown. The list is sorted by the ratio of peptides detected in ALV IN pulldown vs. 








To validate our MS-based results, we next analyzed the affinity pull-down 
fractions by immunoblotting using antibodies directed against SSRP1 or Spt16 proteins. 
The results in Figure 3.2A show that ALV IN interacted with both components of the 
endogenous FACT complex from nuclear extracts of HEK293T cells. In contrast, in 
parallel reactions HIV-1 and MLV INs failed to interact with either SSRP1 or Spt16 
(Figure 3.2A).  Figure 3.2B shows the recombinant purified IN proteins used in Figure 
3.2A. 
As our MS-based results and immunoblotting cannot distinguish between direct 
and indirect interactions; we next performed affinity pull-downs with recombinant 
purified GST-tagged ALV and HIV-1 IN proteins. For these experiments, we used either 
purified recombinant FACT complex or LEDGF/p75. The FACT complex specifically 
interacted with ALV IN but not with HIV-1 IN (Figure 3.2C).  In parallel experiments the 
expected interaction of HIV-1 IN with its known cellular cofactor, LEDGF/p75, but not 















Figure 3.2: The components of the FACT complex, SSRP1 and Spt16, bind ALV IN 
but not HIV-1 or MLV INs. (A) Affinity pull-down results from uninfected nuclear 
lysates of HEK293T  cells (100 µg total protein) with indicated 2 µM 6xHis-tagged 
recombinant retroviral INs, followed by immunoblotting with SSRP1 or Spt16 
antibodies. (B) Coomassie-stained SDS/PAGE gel of recombinant purified INs used in 
panel A.  (C) Coomassie-stained SDS/PAGE gel of affinity pull-down results of 
recombinant purified GST-tagged INs (1 µM) with FACT complex (0.6 µM).  All images 






We next wanted to further dissect the contributions of individual proteins and/or 
domains responsible for interaction between the FACT complex and ALV IN. We first 
examined binding of C-terminally truncated fragments of ALV IN with the FACT 
complex.  The results in Figure 3.3A show that the CTD (consisting of amino acids 208-
286) is essential for binding to the FACT complex as the isolated N-terminal domain 
(NTD) and the two domain fragment containing NTD and catalytic core domain (CCD) 
fail to bind the FACT complex.   
To elucidate contributions of individual components of the FACT complex for 
binding and catalytic activity of ALV IN, we next utilized affinity pull-downs and 
homogenous time resolved fluorescence (HTRF)-based in vitro integration assays 
(Sharma et al., 2013). Figure 3.3B shows that both purified proteins are able to bind ALV 
IN individually. However, both components of the FACT complex were needed to 
effectively stimulate ALV integration activity (~350 percent). In contrast, SSRP1 or 
Spt16 alone failed to enhance ALV IN activity (Figure 3.3C).  The level of stimulation of 
ALV IN activity by the FACT complex is similar to that seen for the addition of 
LEDGF/p75 to HIV-1 IN or Brd4 to MLV IN (Sharma et al., 2013). In parallel 
experiments, HIV-1 IN activity was not significantly stimulated by the addition of 
SSRP1, Spt16 or the FACT complex.  In fact, the addition of either protein suppressed 







Figure 3.3: FACT complex stimulates in vitro integration activity of ALV integrase.  
(A) Schematic of C-terminally truncated constructs of ALV IN with domains and flexible 
linkers indicated. Coomassie-stained SDS/PAGE analysis of affinity pull-down fractions 
using recombinant purified GST-tagged ALV IN, ALV NTD-CCD, and ALV NTD (1 
µM) with FACT complex (0.6 µM).  Lower band in ALV NTD preparation was GST 
alone. (B) Coomassie-stained SDS/PAGE analysis of affinity pull-down fractions using 
recombinant purified GST-tagged ALV IN (1 µM) with FACT complex, SSRP1 or Spt16 
(0.6 µM). All images depict representative results of triplicate experiments with 
molecular weights indicated. (C) HTRF strand transfer integration  activity assay of HIV-
1 or ALV INs (400 nM) with FACT complex, SSRP1 or Spt16 (1.0 µM).  The results 
from triplicate experiments with standard deviations are indicated.  Shown are the HTRF 




ALV proviral integration frequency correlates directly with FACT complex expression 
levels in infected cells. 
 Since the FACT complex binds ALV IN and stimulates its activity in vitro (see 
previous), we hypothesized that the FACT complex could also play a role in regulating 
ALV integration in infected cells. To determine the effect of the FACT complex on ALV 
integration in infected cells, we employed a chicken cell line (DT40) with varying 
expression levels of the FACT complex. Previous research has shown that the expression 
and abundance of the FACT complex is regulated by a complex feedback loop in which 
SSRP1 mRNA plays a critical role (Safina et al., 2013). The presence of SSRP1 mRNA is 
essential for stability of Spt16 protein and the FACT complex as a whole. In the absence 
of SSRP1 mRNA, both protein components are depleted. Similarly, when SSRP1 mRNA 
is overexpressed, Spt16 protein levels also increase (Safina et al., 2013).   
We used a SSRP1 conditional knock-out engineered in the chicken B-cell line, 
DT40, to investigate the functional consequences of the FACT complex on ALV 
integration. This cell line lacks both endogenous copies of the SSRP1 gene but has a wild 
type SSRP1 gene expressed from a tet-repressible promoter (SSRP1
-/-
 + SSRP1) (Abe et 
al., 2011) (see also Figure 3.4A). Because of the demonstrated complex regulation of the 
FACT complex, this cell line, which allowed us to manipulate SSRP1 levels, is ideal for 
controlling the levels of SSRP1, Spt16 and the FACT complex as a whole.  
In the presence of doxycycline, (SSRP1
-/-
) cells exhibited SSRP1 protein levels 
that declined to undetectable levels by 12 hours post treatment, resulting in a cell line 




did not significantly affect cell proliferation during the initial 48 hours after doxycycline 

















Figure 3.4: Validating SSRP1 conditional knockout cell line. (A) Schematic of cell 
line. In a wild type DT40 background, both endogenous loci of SSRP1 were targeted by 
homology constructs (indicated by red box) in order to knock down both copies of the 
gene. A wild type copy of the SSRP1 gene was introduced into cells on a plasmid under 
the control of a tet-repressible promoter. In the absence of doxycycline, SSRP1 is 
expressed (SSRP1
-/- 
+ SSRP1). In the presence of doxycycline, SSRP1 expression is 
ablated (SSRP1
-/-
). (B) Western blot showing that SSRP1 protein levels decrease to 
undetectable levels by 12 hours after doxycycline addition. Relevant molecular weight 
markers are shown. (C) Growth curve of SSRP1 knockout and wild type cells over 96 
hour period after adding doxycycline. SSRP1 knockout (SSRP1
-/-
) does not significantly 




To analyze how varying levels of SSRP1 could affect ALV integration, we 
compared infections in parental DT40 cells, cells expressing elevated levels of SSRP1 
(SSRP1
-/-
 + SSRP1) or knockout (SSRP1
-/-
) levels of SSRP1. In the manipulated cell line 
(SSRP1
-/-
 + SSRP1), SSRP1 is expressed from an exogenous promoter and is thus not 
expressed at wild type levels. We observed a 5-fold increase in SSRP1 mRNA expression 
in SSRP1
-/-
 + SSRP1 relative to the parental DT40 cell line.  
SSRP1
-/-
 cells express 65- and 10-fold lower SSRP1 mRNA compared with SSRP1
-/-
 + 
SSRP1 and parental DT40 cells respectively (Figure 3.5A). By using these three 
conditions, we can assay for ALV proviral integration frequency at wild type levels, 
overexpressed and knockout levels of SSRP1 and hence the levels of the FACT complex. 
Cells expressing the highest levels of SSRP1 also had the highest levels of ALV 
integration frequency, determined by qPCR analysis of gel-purified DNA. We observed 
an approximately 2-fold increase in proviral integrations in the wild type DT40 cells 
versus knockout cells (SSRP1
-/-
) and a 6-fold increase in integration frequency in cells 
overexpressing SSRP1 (SSRP1
-/-
 + SSRP1) (Fig 3.5B). Thus, the trend in integration 
frequency directly correlates with expression levels of SSRP1 as well as the levels of the 
FACT complex. 
These trends were verified using a second, independent method. In this approach, 
proviral integration frequency was measured from genomic DNA collected from infected 
cells using nested PCR. A first round of PCR was performed to enrich for proviral-host 
genome junctions using a viral specific primer and a consensus primer within the most 
abundant repeat element in the chicken genome (CR1 element).  A second, quantitative 




a significant 12-fold decrease in proviral integrations in infected SSRP1 knockout cells 
relative to SSRP1
-/-
 + SSRP1 cells (Figure 3.5C). The parental DT40 cell line had an 
intermediate level of integration consistent with SSRP1 expression levels. These data 
show that ALV proviral integration frequency is directly correlated to FACT complex 






















Figure 3.5: ALV proviral integration frequency correlates directly with SSRP1 





+ SSRP1 cells. The expression levels of SSRP1 mRNA were measured relative 
to a housekeeping gene, RPL30 by qRT-PCR. In the knockout condition (SSRP1
-/-
), 
SSRP1 expression decreased 65- and 10-fold relative to SSRP1
-/- 
+ SSRP1 and parental 
DT40 cells respectively (n=6, p < 0.05). DT40 expression was approximately 6-fold 
lower than expression levels in SSRP1
-/- 
+ SSRP1 cells (n=6, p < 0.05). (B) Analysis of 
integration frequency. Proviral integrations were measured by qPCR from gel purified 
genomic DNA. In the SSRP1 knockout cell line, proviral integration frequency decreased 
6.5-fold relative to cells expressing SSRP1 (SSRP1
-/- 
+ SSRP1) (n=6, p<0.05). DT40 cells 
exhibited approximately 2.5 fold higher expression than knockout cells (n=6, p<0.05). 
(C) Proviral integrations were measured independently using a CR1-gag nested PCR 
approach. Integration frequency decreased by 12-fold in the absence of SSRP1 expression 
(SSRP1
-/- 
) relative to SSRP1
-/- 






















The FACT complex regulates ALV at the level of integration 
Because the proteins of the FACT complex interacted with ALV IN, we 
hypothesized that this complex is specifically regulating the ALV life cycle at the level of 
integration. However, the observed change in the number of detectable proviral 
integration events could be due to effects of the FACT complex at various levels of the 
retroviral life cycle preceding or during integration. For instance, if the FACT complex 
affects reverse transcription, nuclear import or integration, then one would expect to 
detect less integrants in the SSRP1 knockout (SSRP1
-/-
) cells.  
To distinguish between these possibilities, we quantified various retroviral 
intermediates. Plus strand extension (PSE) products are an intermediate of the retroviral 
life cycle produced by the late steps of reverse transcription and the abundance of PSE 
products can be used to assay variations in reverse transcription (Karageorgos et al., 
1995). There was no significant difference in the levels of PSE products between the 
knockout (SSRP1
-/-
) cells versus cells expressing SSRP1 (SSRP1
-/- 
+ SSRP1) indicating 
that reverse transcription is not affected by the levels of the FACT complex (Figure 
3.6A).  
Once viral cDNA is reverse transcribed, it enters the nucleus of the host cell as 
part of the pre-integration complex. Within the nucleus, the non-homologous end-joining 
pathway circularizes unintegrated viral genomic DNA to generate 2-LTR circles. These 
circularized viral intermediates can be used as a proxy to measure the abundance of 
unintegrated nuclear viral genomes (Butler et al., 2001; Mandal and Prasad, 2009). The 
unique LTR-LTR junction present in this intermediate makes it readily detectable and 




detected in the SSRP1 knockout (SSRP1
-/-
) cells versus cells expressing SSRP1 (SSRP1
-/-
 
+ SSRP1) (Figure 3.6B). A decrease in proviral integration accompanied by an increase 
in unintegrated nuclear viral products, specifically 2-LTR circles, indicates that nuclear 
import is not blocked and that the integration step is significantly impaired in the absence 























Figure 3.6: The FACT complex promotes ALV integration. To determine the step of 
the life cycle that the FACT complex is affecting, retroviral intermediates were assayed 
by qPCR. (A) The FACT complex does not disrupt reverse transcription. Abundance of 
plus strand extension (PSE) products, a product of late reverse transcription, was 
measured by qPCR using primers within gag. There was no significant difference in PSE 
product abundance observed between SSRP1 knockout (SSRP1
-/-
) and cells expressing 
SSRP1 (SSRP1
-/- 
+ SSRP1) (n=3). (B) The FACT complex specifically promotes ALV 
integration. The abundance of 2-LTR circles was measured by qPCR in cells expressing 
SSRP1 (SSRP1
-/- 
+ SSRP1) and SSRP1 knockout (SSRP1
-/-
) cells. A 10-fold increase in 2-
LTR circles was detected in the SSRP1 knockout cells (n=4, p<0.005) indicating that 




Knockdown of the FACT complex does not inhibit lentiviral or gamma-retroviral 
integration 
We next wanted to know if the regulation of integration by the FACT complex 
was specific to ALV or could also affect other retroviruses. As such, we infected 
knockout cells (SSRP1
-/-
) or cells overexpressing SSRP1 (SSRP1
-/-  
+ SSRP1) with VSV-
G pseudotyped MLV or HIV-1. There was no significant difference in the frequency of 
MLV or HIV-1 proviral integration in the knockout (SSRP1
-/-
) cells relative to cells 
expressing SSRP1 (SSRP1
-/- 
+ SSRP1) (Figure 3.7). The levels of plus strand extension 




















Figure 3.7: The FACT complex does not promote gamma-retroviral or lentiviral 
integration. (A) The FACT complex does not affect MLV integration. MLV proviral 
load was measured in infected cells by qPCR using viral specific primers relative to 
GAPDH. No significant difference in MLV integration frequency was observed in the 
SSRP1 knockout cells (SSRP1
-/-
) relative to cells expressing SSRP1 (SSRP1
-/- 
+ SSRP1). 
(B) HIV-1 proviral load was not affected by varying abundance of SSRP1. HIV-1 
integration frequency was measured by qPCR using viral specific primers relative to 
GAPDH. No significant difference in HIV integration frequency was observed in the 
SSRP1 knockout cells (SSRP1
-/-
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The FACT complex has subtle effects on ALV integration pattern in vivo 
 We hypothesized that the FACT complex might be targeting ALV integration due 
to the wide distribution of FACT complex throughout the genome, which is fitting with 
the observed random integration pattern for ALV. To test this we performed integration 
site mapping as previously described (Justice et al., 2015a) on our modified cell line 
(SSRP1
-/- 
+ SSRP1) or FACT knockout (SSRP1
-/-
)  cells. For each sample, we performed 
at least 2 biological replicates. We also made use of two distinct integration site mapping 
methods. The first is a sonication-based method that randomly fragments DNA for library 
preparation. The second method makes use of restriction digest to fragment the genome 
and is used to eliminate background from unintegrated viral products. Data from both 
methods agreed and thus, the data shown here is from the sonication-based library 
preparations due to reduced sequencing bias. 
 To preliminarily address whether the FACT complex might be targeting ALV 
integration in chicken cells, we analyzed integration site distribution using the HOMER 
bioinformatics toolkit. We recovered 13,277 and 12,692 unique integration sites for 
SSRP1
-/-
 + SSRP1 and SSRP1
-/-
 cell lines respectively. Looking at major genomic 
annotations such as transcription start sites (TSS), genes, promoters, CpG islands, and 
satellite sequences revealed that levels of SSRP1 have small effects on integration 
distribution in vivo (Figure 3.8). The largest effect observed was the increased preference 








Figure 3.8: Analysis of integration site pattern using HOMER bioinformatics 
program. Shown is the enrichment of integration into specific genomic features relative 











Varying levels of FACT complex also had an effect on integration in the 
proximity of transcription start sites (Figure 3.9). We used HOMER bioinformatics tools 
to map each integration site to the nearest transcription start site (TSS). We then analyzed 
the 10 kb region flanking the TSS and plotted proportion of genes as a function of 
location relative to the TSS. We observed that when functional FACT complex is 
depleted, there is a significant decrease in integration in the proximity of the TSS 
(p=0.0004) Because the FACT complex plays a role in facilitating transcription it often 
co-localizes with RNA polymerase II, which has been shown to be poised near the TSS 
(Core and Lis, 2008). Thus, our evidence supports a role for the FACT complex in 

















Figure 3.9: Integration of ALV relative to TSS in WT and SSRP1 knockout cell 
lines. Integration frequency is plotted as a function of distance from the transcription start 
site where the TSS is set to 0. Shown are the integration frequencies for cells with 
functional fact complex (SSRP1
-/-
 + SSRP1) and those without (SSRP1
-/-
). ROC analysis 
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We find that the presence or absence of functional FACT complex had no effect 
on integration location within the gene body (Figure 3.10). We also correlated integration 
with gene expression levels and extent of splicing. We saw no significant differences 
between cells with functional FACT complex and the knockout cells in any category 
(Figure 3.11). Lastly, the sequence preference at the site of integration was not 
appreciably affected by the FACT knockout (Figure 3.12). Integration pattern in the 
SSRP1
-/-
 and the SSRP1
-/-
 + SSRP1 cell lines agreed with the observed distribution of 











Figure 3.10: Integration location throughout the gene body is not altered by SSRP1 
knockout. Of integrations that fell within a transcription unit, we analyzed where 
integrations were located throughout the gene body. To do this, we divided the gene body 
into 20 bins and plotted percent integrations that fell within each bin. A total of 2484 and 
2425 integrations mapped within gene bodies for SSRP1
-/-
 + SSRP1 and SSRP1
-/-
 
respectively. Data for cells with functional fact complex (SSRP1
-/-
 + SSRP1) are shown 
in green and those without (SSRP1
-/-











Figure 3.11: ALV integration into expressed and spliced genes is unaffected by 
knockout of the FACT complex. (A) To determine if the FACT complex affected 
integration into expressed genes, we analyzed the expression of the gene most proximal 
to the site of integration. We binned expression into 11 bins based on FPKM values and 
plotted percent of integrations that fell into each expression bin. Data for cells with 
functional fact complex (SSRP1
-/-
 + SSRP1) are shown in blue and those without 
(SSRP1
-/-
) are shown in red. (B) The extent of splicing of the most proximal gene to the 
site of integration was analyzed by plotting the percent of integrations that occur near 
genes based on the number of introns in that gene. Data for SSRP1
-/-
 + SSRP1 is shown 
in green and SSRP1
-/-






Figure 3.12: Integration site sequence preference is not altered by levels of the 
FACT complex. Nucleotide frequency at each base surrounding the site of integration is 
shown for cells expressing functional FACT complex and cells in which FACT complex 



































































































































































































































































































































Common sites of integration differ between cells with and without functional FACT 
complex 
 Certain genes are hotspots of integration and accrue multiple integrations. We 
analyzed recurrent integration genes (RIGs) between cells with and without functional 
FACT complex. RIGs in wild type cells seemed to be on average less targeted in FACT 
knockout cells (Figure 3.13A). To determine if the RIGs for each condition were 
enriched in any particular cellular pathways, we performed gene ontology analysis of all 
RIGs (defined as genes with 2+ integrations). Interestingly, the most enriched GO terms 
were all transcription factor binding sites and enriched transcription factor binding sites 
differed between conditions (Figure 3.13B) supporting the hypothesis that the FACT 


















Figure 3.13: RIGs and GO term enrichment of RIGs in wild type vs. FACT 
knockout cells. Integration sites were mapped to the nearest gene. Number of 
integrations per gene was calculated and RIGs were identified as genes with 2+ 
integrations. (A) Shown is a heatmap of percent of integrations into individual genes in 
wild type vs. FACT knockout cells. The top 25 most commonly targeted genes in wild 
type cells were analyzed. (B) All RIGs were used to analyze GO term enrichment. Genes 
were entered using the ordered query feature of gProfiler which weights genes according 
to how many integrations were detected. Shown are significantly (p<0.05) enriched 






In this study, we have identified the FACT protein complex, which is comprised 
of SSRP1 and Spt16, as the principal cellular binding partner of ALV IN. While ALV IN 
interacts with both SSRP1 and Spt16 individually, the FACT complex as a whole is 
required to stimulate integration activity in vitro. Additionally, we have demonstrated the 
importance of ALV IN CTD for binding to the FACT complex. Furthermore, we show 
that the level of ALV integration positively correlates with the abundance of the FACT 
complex in infected cells. The levels of 2-LTR circles were elevated when the FACT 
complex was depleted, demonstrating that this complex is critical for the integration step 
of the ALV life cycle. The level of plus strand extension products was unaffected by the 
levels of the FACT complex, indicating that the FACT complex does not affect reverse 
transcription. Taken together, our results elucidate a key role of the FACT complex in 
promoting ALV integration in infected cells. This regulation is likely not species-specific 
as interactions of ALV IN and the FACT complex were detected in both human and 
chicken cells.  This is similar to what is seen for other retroviruses such as MLV IN 
which interacts with BET proteins from human and murine cells due to the high degree of 
conservation in chromatin binding proteins (Sharma et al., 2013). 
Our findings indicate that the regulation of integration by the FACT complex is 
specific to alpharetroviral ALV. Unlike ALV IN, HIV-1 and MLV INs failed to bind the 
FACT complex. Moreover, MLV and HIV-1 integration was not significantly affected by 
altering the cellular levels of the FACT complex in infected cells.   
HIV-1 and MLV exhibit strong integration site preferences for actively 




enhancers, respectively (Lewinski et al., 2006; Schröder et al., 2002; Wu et al., 2003). In 
sharp contrast, ALV integration is relatively random and does not seem to target such 
regions as strongly (Chapter 2; Barr et al., 2005; Mitchell et al., 2004; Narezkina et al., 
2004; Withers-Ward et al., 1994).  Previous research has shown that the distinct 
integration site preferences of retroviruses can be linked to interaction of the virally 
encoded IN protein with various host cell factors (Craigie and Bushman, 2014; Debyser 
et al., 2015; Kvaratskhelia et al., 2014).  Mechanistically, these host cell factors act 
largely as a bimodal tether to recruit the pre-integration complex to the chromatin thereby 
targeting proviral integrations (Kvaratskhelia et al., 2014). For example, LEDGF/p75 
engages HIV-1 IN through its C-terminal integrase binding domain and guides HIV-1 
integration to active genes (Cherepanov et al., 2003, 2005; Ciuffi et al., 2005; Llano et 
al., 2006; Maertens et al., 2003). The selection of the chromatin sites for integration is 
affected by the preferential binding of the N-terminal PWWP domain of LEDGF/p75 
with the H3 histone tail containing trimethylated Lys36 (H3K36me3) a hallmark of 
actively transcribed genes (Eidahl et al., 2013). In a very similar manner, BET proteins, 
with their dual bromodomains, are able to guide MLV integration by bimodal interaction 
with both MLV IN and acetylated histone marks (Crowe et al., 2016; Larue et al., 2014; 
Sharma et al., 2013).   
The FACT complex is believed to destabilize the histone octamer providing 
access to the chromosomal DNA for various enzymes (Formosa; Reinberg and Sims, 
2006; Winkler and Luger, 2011).  In particular, the C-terminal tail of Spt16 displaces 




capability to make chromatin more accessible by loosening or releasing the chromosomal 
DNA could allow for more effective integration.  
In fact, a recent report shows that the chromatin states generated by 
overexpression or knockout of the FACT complex promote HIV-1 integration (Matysiak 
et al., 2017). This activation of HIV-1 integration was found to be dependent on the 
presence of nucleosomes and the chromatin remodeling activity of the FACT complex. 
The activation was recapitulated when chromatin states similar to those generated by 
FACT complex activity were artificially induced indicating that it is indeed the structures 
generated that promote HIV-1 integration. This mechanism differs from what we observe 
here for ALV integration. The FACT complex directly binds ALV integrase and 
integration is clearly correlated with FACT complex abundance. This suggests that the 
FACT complex may be acting as a tether to recruit the pre-integration complex to the 
chromatin similar to what is observed for LEDGF and HIV-1.  
The evidence presented here strongly supports a role for the FACT complex in 
promoting ALV integration in vitro and in vivo. We see subtle effects of FACT knockout 
on ALV integration pattern, such as a depletion of integrations around the TSS and 
enrichment for integrations into satellite sequences. The depletion of integration in 
proximity to the TSS is consistent with a role for the FACT complex in tethering the PIC 
to predicted FACT binding sites thereby influencing integration nearby. Unfortunately, 
FACT binding data is not available for chickens and thus, further work is necessary to 
conclusively show that the FACT complex is indeed acting as a tether. The enrichment of 
integrations in satellite sequences in the absence of FACT complex is interesting. While 




in general are often found in heterochromatic regions. I hypothesize that the FACT 
complex may normally be targeting integration to euchromatic regions where it would be 
localized, and in the absence of FACT, integration is redirected to heterochromatin. This 
could be due to an innate preference for integration into heterochromatin or the result of a 
secondary targeting factor that takes over in the absence of the FACT complex. Further 
studies are necessary to elucidate the exact mechanism for regulation of ALV integration 
by the FACT complex, which could in turn facilitate the development of ALV-based 
























Chapter 4 – Other host cell factors that regulate ALV replication: BET proteins, 





















 In addition to the two components of the heterodimeric FACT complex, Brd2, 
NCL (nucleolin) and UBTF (upstream binding transcription factor) were identified as 
specific binding factors of the ALV integrase protein in an affinity coupled mass 
spectrometry screen. Brd2 is a member of the BET family of proteins known to be 
important for regulating MLV integration. NCL has multiple functions including histone 
chaperone activity similar to that of the FACT complex. UBTF is a RNA polymerase I 
specific factor. Here we show that while NCL and UBTF do not directly affect 
integration of ALV, BET proteins seem to regulate ALV integration in competition with 
the FACT complex. To support this we find a role for BET proteins in inhibiting 
integration efficiency, but this effect is superseded by the effect of the FACT knockout. 
Further, while BET protein inhibition detectably affects integration targeting alone, 
inhibition in the context of a FACT knockdown has a larger effect on integration pattern. 
These data combined suggest that BET proteins may play a secondary role in both 













 Given that the FACT complex only had subtle effects on integration targeting, we 
hypothesized that additional host cell factors may be regulating ALV integration in 
addition to the FACT complex. While the FACT complex proteins (SSRP1 and SPT16) 
were the most promising hits to emerge from our screen for ALV integrase binding 
partners, other candidates that specifically bound ALV integrase were detected (Table 
3.1). Other candidate host cell factors include Brd2, NCL (nucleolin) and UBTF 
(upstream binding transcription factor).  
 Brd2 is a member of the BET (bromodomain and extra terminal) family of 
proteins that includes Brd2, Brd3 and Brd4. Through their bromodomains, BET proteins 
interact with acetylated lysines of histone tails, specifically those of the H4 histone 
(Florence and Faller, 2001). BET proteins have known roles in regulating transcriptional 
elongation, cell cycle regulation and cancer (Florence and Faller, 2001). The BET family 
of proteins has also previously been shown to target MLV integration to transcription 
start sites and CpG islands by acting as a bimodal tether (Larue et al., 2014; De Rijck et 
al., 2013; Sharma et al., 2013). Brd4 specifically has been shown to antagonize 
transcription of HIV-1 (Bisgrove et al., 2007; Zhu et al., 2012a). BET proteins have also 
been shown to regulate the replication of many other viruses in various ways including 
the human herpesviruses, Epstein Barr virus (EBV) and Kaposi’s sarcoma herpesvirus 
(KSHV), as well as papillomaviruses (Ilves et al., 2006; Lin et al., 2008; You et al., 
2006). 
 Nucleolin is a multifaceted protein with various functions. Nucleolin was initially 




rRNA processing (Ginisty et al., 1998; Rickards et al., 2007). However, it has since been 
shown to also be found at the cellular membrane where it plays a role in mediating viral 
entry into host cells for various viruses such as human parainfluenza virus and respiratory 
syncytial virus (Bose et al., 2004; Tayyari et al., 2011). Interestingly, NCL also directly 
binds and regulates the RNA-dependent RNA polymerase of Hepatitis C virus (HCV) 
(Hirano et al., 2003). NCL has also been shown to regulate capsid assembly of adeno-
associated virus (AAV) and be important for the episome maintenance functions of the 
EBNA1 protein of Epstein-Barr virus (Chen et al., 2014; Qiu and Brown, 1999). 
Nucleolin (NCL) is a particularly interesting candidate in our screen due to its functional 
similarity to the FACT complex (Angelov et al., 2006; Mongelard and Bouvet, 2007). In 
fact, the only proteins ever described to stimulate transcription from a chromatin template 
in vitro are the FACT complex, nucleolin and Brd2 (Angelov et al., 2006; LeRoy et al., 
2008; Orphanides et al., 1998). That all of these proteins were found to specifically bind 
ALV integrase suggests that there may be a critical shared feature that the integrase 
protein binds or a common function that promotes integration. 
 Lastly, UBTF (upstream binding transcription factor) is a required component of 
the RNA polymerase I initiation complex (Kwon and Green, 1994). It has also been 
implicated in pre-ribosomal RNA processing as well as chromatin remodeling (Sanij et 
al., 2015). It has been described as an inhibitor of herpes simplex virus replication in vivo 
(Ouellet Lavallée and Pearson, 2015). 
 Here we find that BET proteins alone have a negative effect on ALV integration 
efficiency in vivo and subtle effects on ALV integration targeting. Interestingly, there 




of the FACT complex, BET protein inhibition promotes ALV integration, however in the 
absence of the FACT complex, BET inhibition inhibits ALV integration efficiency. The  
fact that the FACT knockout phenotype is epistatic to the BET inhibition phenotype 
indicates that the FACT complex is likely the main host factor that regulates ALV 
integration and BET may act as a secondary factor. It seems though that while the FACT 
complex normally promotes ALV integration, BET proteins may inhibit the process. 
Inhibition of BET protein function has a stronger effect on ALV integration pattern when 
the FACT complex is absent further indicating that FACT may be the primary cofactor of 
ALV while BET proteins play a less important role. We further find that the other 


















BET protein inhibition affects ALV integration efficiency in vivo 
 Brd2 was the 3
rd
 most enriched protein in the ALV integrase pulldown fraction in 
our original mass spectrometry screen. Brd2 belongs to the BET family of proteins which 
include Brd2, Brd3 and Brd4. JQ1 is a small molecule inhibitor of BET protein binding 
to the chromatin (Filippakopoulos et al., 2010) . In order to assess whether BET proteins 
regulate ALV integration, we treated cells with JQ1 to inhibit BET protein function and 
infected with either ALV or MLV as a positive control (Figure 4.1). As expected, we see 
that MLV integration decreases by approximately 2-fold (p<0.005) when BET protein 
function is inhibited in agreement with previous publications (Aiyer et al., 2014; De 
Rijck et al., 2013; Sharma et al., 2013). However, we observed that in the absence of 
BET protein function, ALV integration efficiency actually significantly increased by 














Figure 4.1: BET protein inhibition promotes ALV integration efficiency in vivo. 
DT40 cells were treated with JQ1, a small molecule inhibitor of BET protein function. 
Cells were then infected with either MLV, as a positive control, or ALV. Integration 
efficiency was measured using CR1-gag nested PCR approach and normalized to 
GAPDH. Shown are the fold changes in integration frequency after JQ1 treatment 









To determine if the observed effect of BET protein inhibition on ALV integration 
efficiency was at the level of integration we measured other viral intermediates such as 
reverse transcription (RT) products and 2-LTR circles. There was no detectable 
difference in RT product abundance, indicating that entry and RT occur comparably in 
the presence or absence of functional BET proteins (data not shown). We next looked at 
2-LTR circle abundance. 2-LTR circles can serve as a marker for nuclear import as well 
as failed integration. If nuclear import is compromised, 2-LTR circle levels decline. On 
the other hand, if integration is blocked, 2-LTR circle abundance increases (Butler, 
Hansen, and Bushman 2001; Mandal and Prasad 2009). As expected in the case of MLV, 
where BET proteins are known to directly promote integration, JQ1 treatment led to a 
significant increase in 2-LTR circle levels (Figure 4.2). Interestingly, ALV 2-LTR circle 
abundance decreases in the presence of JQ1. This could indicate that nuclear import is 
compromised, but the lower 2-LTR circle levels in conjunction with higher integration 
frequency likely indicates that integration is directly being promoted when functional 





Figure 4.2: BET protein inhibition causes a decrease in ALV 2-LTR circle levels. 
DT40 cells were treated with JQ1 to inhibit BET protein infection and infected with 
either MLV or ALV. 2-LTR circle abundance was measured using qPCR and normalized 
to GAPDH. Shown is the fold change in abundance in JQ1 treated cells vs. untreated 











BET protein inhibition has subtle effects on the ALV integration pattern in vivo 
 Our evidence suggests that BET proteins play a role in inhibiting ALV 
integration, opposite to the effect of the FACT complex. We next analyzed whether this 
effect on ALV integration frequency was accompanied by an effect on targeting. To 
determine this we mapped ALV integration sites in WT DT40 cells in the presence or 
absence of the BET protein small molecular inhibitor JQ1. We specifically chose to look 
at transcription start sites, promoters, genes and CpG islands because these are known 
BET protein binding sites. The inhibition of BET proteins in a wild type background had 
little effect on integration into any of these features (Table 4.1). The most notable 
difference was integration into genes, which changed by roughly 4% (p < 0.1). Upstream 
of the TSS, in the promoter region, BET protein inhibition also decreased integration (p < 
0.1). Integrations in the transcription start sites and CpG islands were not significantly 

















Annotation WT WT+JQ1 
within 5kb of TSS 10.5 9.0 
5 kb upstream of TSS 7.6 5.9 
RefSeq genes 37.9 41.6 
CpG-Island 3.8 2.8 
 
Table 4.1: Integration frequency in common genomic features in wild type and JQ1-
treated wild type cells. Percent of detected ALV integrations that fell within each 
specified category was determined using HOMER bioinformatics tools. Significant 













FACT complex and BET proteins seem to have competing effects on ALV integration 
 We next wanted to examine whether the FACT complex and BET proteins had 
competing effects on ALV integration in vivo. In order to do this, we inhibited BET 
protein function in the presence of varying levels of FACT complex (Figure 4.3). In wild 
type cells and FACT complex overexpressing cells, BET protein inhibition promoted 
ALV integration efficiency. Interestingly, the more FACT complex present, the larger the 
effect of BET protein inhibition was. However, when BET protein function was inhibited 
in a FACT knockout background, integration efficiency actually decreased. This 
phenotype is comparable to what is seen with the FACT knockout alone, indicating that 








Figure 4.3: Effect of BET protein inhibition on ALV integration efficiency in the 
presence of varying levels of the FACT complex. Cells with either overexpressed, wild 
type or knockout levels of FACT complex were treated with JQ1 to inhibit BET protein 
function. ALV integration efficiency was then measured using CR1-gag nested qPCR 
approach and normalized to GAPDH. Plotted is the ratio of integration observed in JQ1 





















































Since our data suggested that BET proteins may play a less important role in 
regulating ALV integration as compared to the FACT complex, we reasoned that perhaps 
BET protein inhibition might more appreciably affect ALV integration pattern in the 
absence of the FACT complex, the primary host cell factor. Thus, we mapped integration 
sites in FACT knockout cells or JQ1-treated FACT knockout cells. Percent of 
integrations into selected genomic features is shown in Table 4.2. We observe a nearly 2-





















Annotation FACT KO FACT KO + JQ1 
within 5kb of TSS 4.7* 8.3* 
5 kb upstream of TSS 3.3 4.0 
RefSeq genes 35.8* 40.7* 
CpG-Island 4.8 3.8 
 
Table 4.2: Integration frequency of ALV into various genomic features in FACT 
knockout and FACT knockout JQ1 treated cells. Percent of integrations into the listed 
genomic features was calculated using HOMER bioinformatics tools. Significant 















 However, to further interrogate any potential differences, we took a closer look at 
integrations in the proximity of transcription start sites and CpG islands. We did this for 
all four of our tested conditions (wild type, wild type JQ1 treated, FACT knockout and 
FACT knockout JQ1 treated). There was no difference in integration in the proximity of 
these features between the wild type and JQ1-treated wild type cells (data not shown). 
However, there were striking differences in integration near both transcription start sites 
and CpG islands when FACT knockout cells were treated with JQ1 to inhibit BET 
protein function (Figure 4.4). We observe that when BET protein function is inhibited, 
there are more detectable integrations in the region flanking the transcription start site 
(Figure 4.4A) and less integration in the region surrounding CpG islands (Figure 4.4B). 
This seems to indicate that normally BET proteins may have two roles in ALV 
integration targeting - occluding ALV integration near the TSS and promoting integration 
near CpG islands. The fact that these effects are only evident in the absence of the FACT 







Figure 4.4: Integration in the proximity of transcription start sites and CpG islands 
in FACT knockout and JQ1-treated FACT knockout cells. Integration in the 
proximity of both features was calculated using BedWindow to determine the number of 
integrations that fell within a specified window surrounding the genomic feature. This 
was then normalized to total detected integrations. Shown is the percent integrations that 









UBTF affects early steps of ALV life cycle 
 After Brd2, the 4
th
 most enriched protein that bound specifically to ALV integrase 
was UBTF (upstream binding transcription factor). To determine the effect of UBTF on 
ALV replication, we made use of targeted siRNA against human UBTF to knock down 
expression levels in HEK293T cells (Figure 4.5A). A single siRNA was sufficient to 
reduce UBTF expression levels approximately 8-fold (p<0.05) relative to a scrambled 
siRNA control. 
We then infected UBTF knockdown cells with pseudotyped ALV and measured 
ALV integration frequency (Figure 4.5B). We observed an approximate 2-fold reduction 
in proviral integration frequency (p<0.05). However, because integration is the final step 
in the early life cycle of retroviruses, any effect of the knockdown on earlier viral 
processes would also manifest as a reduction on proviral load. Thus, we measured plus 
strand extension products (PSE), a late product of reverse transcription (Figure 4.5C). We 
observed that in cells with depleted UBTF expression, there was a 7-fold decrease in PSE 
products (p<0.05). This indicates that the absence of UBTF has a significant effect on the 
process of reverse transcription. We also did not observe any differences in 2-LTR circle 
abundance between wild type and UBTF knockdown cells (data not shown). Taken 
together, these data indicate that UBTF may be playing a role in regulating reverse 





Figure 4.5: UBTF affects ALV replication. (A) siRNA mediated knockdown of UBTF. 
Expression levels of UBTF were measured in cells transfected with siRNA targeting 
either UBTF or a scrambled control using qPCR. Expression was normalized to a 
housekeeping gene, GAPDH (*p<0.05). (B) CR1-gag nested qPCR was used to measure 
proviral integration frequency. Proviral load was normalized to a housekeeping gene, 
GAPDH. Shown is the fold change in detectable integrants relative to the scrambled 
control (*p<0.05). (C) Plus strand extension products were measured using primers in 







NCL has no effect on ALV replication 
 Nucleolin (NCL) was also significantly enriched in our screen for ALV integrase 
binding partners. NCL also has functional similarity to the FACT complex making it an 
intriguing candidate gene. To determine if NCL may be affecting ALV replication, we 
knocked down NCL expression levels in HEK293T cells using targeted siRNA (Figure 
4.6A). Two individual siRNA both depleted NCL expression levels, one to essentially 0 
and the other roughly 3-fold (p<0.05).  
 To determine affects of NCL on the ALV life cycle, we infected cells transfected 
with siRNA targeting either NCL or a scrambled control with pseudotyped ALV and 
measured ALV integration frequency (Figure 4.6B). We observed no significant 
differences in ALV proviral integration frequency when NCL was knocked down. Thus, 





Figure 4.6: NCL has no effect on ALV integration. (A) Expression levels of NCL were 
measured in cells transfected with siRNA targeting NCL or a scrambled control using 
qPCR and normalized to GAPDH. (B) Proviral integration frequency was determined 



























































































 We find that nucleolin (NCL) and UBTF have no direct role in regulating ALV 
integration. NCL knockout had no effects on ALV integration efficiency in cultured cells 
in vitro. It is possible that the presence of functional FACT complex masks any affects 
the NCL knockout may have had. However, this is difficult to test in our hands due to the 
fact that our established FACT knockout cell line system is constructed in B-cells which 
are unable to be efficiently transfected making siRNA mediated knockdown difficult. 
UBTF knockdown did have affects on ALV integration frequency in a wild type 
background, however it was determined based on reverse transcription (RT) product 
abundance that this was the result of compromised RT in the absence of UBTF. 
 Interestingly, inhibition of the BET proteins did seem to have an effect on ALV 
integration. In the presence of overexpressed FACT complex, BET protein inhibition 
increased ALV integration efficiency nearly 5-fold. In a wild type background, BET 
protein inhibition increased ALV integration frequency to a lesser extent, about 2-fold. In 
the absence of functional FACT complex however, ALV integration efficiency was 
decreased. We believe this indicates that the FACT complex and BET proteins have 
competing effects on ALV integration. BET proteins inhibit ALV integration while 
FACT complex promotes integration. In the case of overexpressed FACT, when BET 
protein inhibition of integration is relieved, abundant FACT promotes integration to a 
large extent. This effect is less pronounced in the wild type situation because there is less 
FACT complex present to promote integration. Finally, in the case of the FACT 
knockout, lifting the normal inhibition of ALV integration by the BET proteins has no 




knockout phenotype is dominant. This seems to suggest that the FACT complex plays a 
more primary role in regulating ALV integration efficiency while effects of the BET 
proteins may be secondary. This is supported by the fact that ALV integration targeting is 
only appreciably affected by BET protein inhibition when functional FACT complex is 
absent. 
 This model needs to be further tested. An obvious way to do so would be to test 
BET protein binding to ALV integrase in vitro. If BET does indeed bind ALV IN, then 
competitive binding experiments with FACT complex components would be valuable. 
More integration site mapping data in chickens and humans would also be helpful. Our 
analyses were limited by the relatively small number of integration sites. Further, our 
analysis was performed in chicken cells, which limits the features we are able to analyze 
simply due to a poorly annotated reference genome. If these experiments were repeated in 
human cells for which BET protein and FACT complex binding data is available, 
proximity of integrations to these locations could be calculated and potentially reveal 

















Chapter 5 - Integration of ALV into CTDSPL and CTDSPL2 genes in B-cell 












Adapted from:  
Winans S., Flynn A., Malhotra S., Balagopal V., Beemon K. (2017). Integration into 
CTDSPL and CTDSPL2 genes in B-cell lymphomas promotes cell immortalization, 








Avian leukosis virus induces tumors in chickens by integrating into the genome 
and altering expression of nearby genes. Thus, ALV can be used as an insertional 
mutagenesis tool to identify novel genes involved in tumorigenesis. Deep sequencing 
analysis of viral integration sites has identified CTDSPL and CTDSPL2 as common 
integration sites in ALV-induced B-cell lymphomas, suggesting a potential role in driving 
oncogenesis. We show that in tumors with integrations in these genes, the viral promoter 
is driving the expression of a truncated fusion transcript. Overexpression in cultured 
chick embryo fibroblasts reveals that CTDSPL and CTDSPL2 have oncogenic properties, 
including promoting cell migration. We also show that CTDSPL2 has a previously 
uncharacterized role in protecting cells from apoptosis induced by oxidative stress. 
Further, the truncated viral fusion transcripts of both CTDSPL and CTDSPL2 promote 















 Our lab has previously identified CTDSPL (C-terminal domain small 
phosphatase-like) and CTDSPL2 (C-terminal domain small phosphatase-like 2) as 
common integration sites in ALV-induced B-cell lymphomas (Justice et al., 2015b). The 
recurrence and selection of integrations within these genes in tumors suggests that they 
may be involved in driving tumorigenesis. The CTDSP family of proteins consists of 
CTDSP1, CTDSP2, CTDSPL and CTDSPL2 proteins, all of which contain a catalytic 
FCP1 (F-cell production 1) homology domain that functions as a phosphatase (Yeo et al., 
2003). The CTDSP family has been shown to dephosphorylate the C-terminal domain 
(CTD) of RNA polymerase II in vitro (Thompson et al., 2006; Yeo et al., 2003). Through 
this function, this family of proteins is proposed to be important for transcriptional 
regulation. Most family members preferentially dephosphorylate Ser5 of the CTD and 
thus control the transition from initiation to processive transcription elongation 
(Thompson et al., 2006; Yeo et al., 2003). CTDSP1, CTDSP2 and CTDSPL have also 
been shown to play a role in gene silencing, most notably of neuronal gene expression, 
through interaction with the REST complex (Thompson et al., 2006; Visvanathan et al., 
2007; Yeo et al., 2005). 
 The CTDSP proteins are able to act on additional targets as well. For instance, 
CTDSP1/2/L proteins have been shown to induce TGF-β signaling and attenuate BMP 
signaling (Knockaert et al., 2006; Wrighton et al., 2006). CTDSP1 also stabilizes SNAIL 
and C-MYC proteins by dephosphorylating a key serine residue in each protein (Wang et 
al., 2016; Wu et al., 2009). Further, CTDSP1/2/L genes have all been found to contain an 




to act synergistically with the CTDSP1 and CTDSPL proteins to dephosphorylate, and 
thus activate, pRb and block the G1/S cell cycle transition (Zhu et al., 2012b). CTDSP2 
has also been shown to inhibit cell cycle progression independently by activating Ras and 
p21 (Kloet et al., 2015).  
Due to involvement in these pathways, it comes as no surprise that the 
CTDSP1/2/L and the miR-26 family have been implicated in tumorigenesis. CTDSPL has 
been characterized as a tumor suppressor gene that is frequently deleted or mutated in 
many major epithelial cancers such as lung, renal cell and breast carcinoma (Kashuba et 
al., 2004, 2009; Senchenko et al., 2010; Zhu et al., 2012b). Further, all 3 proteins are 
down-regulated in hepatocellular carcinoma cell lines (Zhu et al., 2012b). Comparatively, 
little is known about CTDSPL2. It has been shown to play a role in erythroid 
differentiation and BMP signaling (Wani et al., 2016; Zhao et al., 2014). However, 
CTDSPL2 has not been previously linked to tumorigenesis.  
In this work, we characterize CTDSPL2 as a novel gene involved in oncogenesis 
and further characterize the role of CTDSPL. Specifically, we investigate the function of 
viral induced truncations of both genes in cancer. Overexpression of CTDSPL and 
CTDSPL2 leads to changes in expression of ribosomal genes and genes involved in 
cellular migration and metabolism. We show that overexpression of both CTDSPL and 
CTDPSL2 causes accelerated cellular migration in primary cell culture. Interestingly, 
expression of CTDSPL2, but not CTDSPL, protects cells from apoptosis induced by 
oxidative stress, indicating that the two genes may not be redundant. Importantly, the 
truncated viral fusion transcripts of both CTDSPL and CTDSPL2 promote 






CTDSPL and CTDSPL2 are common integration sites in ALV-induced B-cell lymphomas 
High throughput sequencing was used to identify retroviral integration sites in 
ALV-induced B-cell lymphomas (Justice et al., 2015b). Integration sites that are 
overrepresented in the sequencing data, either because of clonal expansion or because the 
gene is a common integration site between tumors, were selected for and therefore 
believed to be important in tumorigenesis.  
CTDSPL and CTDSPL2 were identified to be common integration sites previously 
(Justice et al., 2015b). In this study we have expanded our analysis and observed 23 
unique clonally expanded integrations in CTDSPL in 12 tumors from 7 birds. All 
expanded integrations are in the same transcriptional orientation as CTDSPL and fall 
upstream of exon 4 (Figure 5.1; Table 5.1). In addition, thirteen unique expanded 
integrations were detected in CTDSPL2 in 7 tumors from 4 birds. All expanded 
integrations in the gene are in the same transcriptional orientation as CTDSPL2 and fall 
upstream of exon 3 (Figure 5.1; Table 5.1). No expanded integrations into either gene 
were observed in non-tumors. Interestingly, we did not observe integration into other 














Figure 5.1: CTDSPL and CTDSPL2 are common integration sites in ALV-induced 
B-cell lymphomas. A schematic of retroviral integrations into both CTDSPL and 
CTDSPL2. Each integration is depicted as an arrow with the base of the arrow 
representing the site of integration. Direction of the arrow indicates the orientation of the 
retroviral integration with respect to transcription of the gene; all are in the sense 
orientation. There are 23 unique expanded integrations in CTDSPL, all of which fall 
upstream of exon 4. There are 13 unique expanded integrations in CTDSPL2 upstream of 





Table 5.1: Genome coordinates, breakpoints and tumor information for integrations 
into CTDSPL and CTDSPL2. All clonally expanded integrations (2 or more 
breakpoints) detected in the screen are listed with tumor ID, number of breakpoints and 
genomic coordinates that correspond to the site of integration. CTDSPL coordinates are 







































Breakpoints Tumor ID Locus # 
71 C3K 4519921 
53 C3L 4519921 
51 D2K 4520683 
26 D2K 4519498 
25 D2K 4519227 
24 D2L 4520683 
22 D2B 4520683 
18 D5S 4515471 
16 D2L 4519227 
14 A1B 4511874 
13 D5L 4515471 
12 D2K 4527016 
10 C2B 4523438 
6 C2B 4517279 
5 D2L 4519498 
5 D2B 4519498 
5 D2B 4527016 
4 D2L 4519620 
4 B6B 4520674 
4 D2L 4524658 
4 D2L 4526898 
4 D2K 4526898 
4 D2L 4527016 
3 D2B 4519344 
3 D2K 4519620 
3 D2B 4519675 
3 C3K 4519923 
2 D5B 4515471 
2 D9B 4517448 
2 D5S 4517790 
2 D2B 4519227 
2 D2K 4519827 
2 D2K 4520864 
2 D2K 4521356 
2 C3L 4523454 





Breakpoints Tumor ID Locus # 
47 D2K 19283543 
42 D2K 19283421 
18 D2B 19283421 
15 D2B 19283543 
15 D2L 19283543 
12 D2L 19283421 
10 D2K 19296421 
9 D2K 19282355 
8 C3L 19284002 
4 D2L 19282355 
4 C3L 19285319 
4 C3K 19296007 
4 D2B 19296421 
3 D3K 19286358 
3 D2L 19296421 
2 D2B 19282355 
2 D2B 19284446 
2 D2K 19284889 
2 C3K 19285319 
2 D2K 19291118 
2 C3L 19296007 
2 D2B 19296037 




Activation of CTDSPL and CTDSPL2 are likely early events in tumorigenesis 
A number of integration sites in the CTDSPL and CTDSPL2 genes were found to 
be highly clonally expanded. Clonal expansion of a specific integration within a tumor 
was estimated via quantitation of sonication breakpoints as described previously (Justice 
et al., 2015b). The highest breakpoint integrations from tumors carrying CTDSPL and 
CTDSPL2 integrations are shown in a composite pie chart in Figure 5.2A. In some 
individual tumors, these integrations were amongst the most dominant, expanded 
integrations (Figure 5.2B). This suggests that these integrations occurred early in 
tumorigenesis and were expanded as the tumor progressed. 
Identical integration sites within both CTDSPL and CTDSPL2 genes were 
identified in primary (bursal) and secondary (liver and kidney) tumors found in the same 
bird (Figure 5.2C). The presence of identical integration sites also indicates that these 
integrations likely occurred early in tumorigenesis prior to metastasis. The primary bursal 
tumor then metastasized to various locations including the liver, kidney and spleen, 
causing the clonal expansion of the integrated provirus in different secondary tumors. 
Interestingly, integrations in CTDSPL and CTDSPL2 frequently occur in the same tumor. 
For instance, primary and secondary tumors in birds C3 and D2 have many of the most 









Figure 5.2: Viral integrations into CTDSPL and CTDSPL2 are an early event in 
tumorigenesis.   (A) A composite pie chart of 11 tumors containing clonally expanded 
integrations in either CTDSPL or CTDSPL2 is shown. In this tumor set, there were 
14,879 unique integrations represented by 20,200 total breakpoints. Integrations having 
40 or more breakpoints are depicted in a separate composite pie chart with individual 
integrations as a single “slice” of the pie chart, weighted by number of breakpoints. There 
are 23 integrations with 40 or more breakpoints. Of these top clonally expanded 
integrations, 3 are in CTDSPL and 2 are in CTDSPL2. (B) CTDSPL and CTDSPL2 are 
dominant integrations in some individual tumors. The top 10 clonally expanded 
integrations are shown for representative tumors (C3L and C3K). In these cases CTDSPL 
and CTDSPL2 are among the most dominant integrations. CTDSPL integrations are 
indicated in blue, CTDSPL2 integrations are indicated in green. Top integrations are 
labeled. (C) Primary (bursa) and secondary (kidney and liver) tumors from the same bird 
(D2) have identical integrations in CTDSPL and CTDSPL2. CTDSPL integrations are 
indicated in blue, CTDSPL2 integrations are indicated in green. The most dominant 
integrations are labeled. Identical integrations in each tumor are indicated with *. These 
integrations are clonally expanded in all cases, comprising a comparable proportion of 
the total tumor breakpoints. This suggests that these integrations occurred early in 














Viral integrations in CTDSPL and CTDSPL2 drive the overexpression of genes. 
Quantitative RT-PCR verified that relative to normal bursa, levels of both 
CTDSPL and CTDSPL2 mRNA were elevated in the tumors with highly clonally 
expanded integrations in these genes (Figure 5.3A). For instance, C3L and C3K had a co-
dominant integration in CTDSPL (Figure 5.2B) and expression of this gene was 
significantly elevated by approximately 2.5- to 3.5-fold respectively. Similarly, D2B and 
D2K had some of the most highly expanded integrations in CTDSPL2 and we observed a 
corresponding 4.5 fold increase in expression (Figure 5.3B). It is interesting to note that 




















Figure 5.3: Tumors with expanded integrations in CTDSPL and CTDSPL2 
overexpress transcripts. (A) qPCR was performed from tumor cDNA for either 
CTDSPL or CTDSPL2 and normalized to a housekeeping gene, GAPDH. Fold change in 
mRNA expression is depicted relative to expression levels in normal bursa (NB). Tumors 
with the most highly expanded integrations in CTDSPL significantly overexpress 
CTDSPL mRNA by 3- to 3.5- fold (C3L and C3K). (B) Likewise, those tumors with the 
most expanded integrations in CTDSPL2 also have a 4.5-fold increase in CTDSPL2 






Integrations in CTDSPL and CTDSPL2 generate truncated fusion transcripts. 
 To determine the mechanism by which the viral integrations are disrupting 
CTDSPL and CTDSPL2 expression, we performed RT-PCR to detect any potential viral 
fusion transcripts. We found that integrations in CTDSPL were driving the expression of 
a fusion transcript from the viral promoter with splicing occurring from the canonical 
splice donor site in gag to the splice acceptor site of exon 4 of the CTDSPL mRNA 
removing 77 amino acids from the N-terminus of the protein (Figure5. 4A). Integrations 
in CTDSPL2 were driving expression of a fusion transcript from the viral promoter with 
splicing occurring from the canonical splice donor site in gag to the splice acceptor site 
of exon 3 of CTDSPL2 removing 63 amino acids from the N-terminus of the protein 
(Figure 5.4A). In both cases, the viral start codon was in frame with the open reading 
frames and would add 6 amino acids of ALV gag at the N-terminus of the fusion protein. 
The truncation did not affect the catalytic phosphatase domain of either protein but did 
remove a portion of a predicted intrinsically disordered region of both proteins (Figure 
5.4B). In the case of CTDPSL2, the truncation also removed a predicted nuclear 











Figure 5.4: CTDSPL and CTDSPL2 transcript truncations induced by viral 
integrations. (A) Schematic of truncated transcripts expressed from integrations in 
CTDSPL and CTDSPL2 as detected by RT-PCR. The promoter in the 5’ LTR of ALV 
drives expression of truncated transcript. Transcripts contain the gag leader sequence 
spliced from the canonical splice donor site (5’ SD) into either exon 4 of CTDSPL or 
exon 3 of CTDSPL2. The ORF is not disrupted in either truncated transcript. (B) PONDR 
plots of CTDSPL and CTDSPL2. PONDR was used to predict intrinsically disordered 
regions of both CTDSPL and CTDSPL2 proteins (Xue et al., 2010). PONDR VL-XT 
score is indicated by red line. Threshold for disorder is set at 0.5 and indicated by a 
horizontal line. Significant stretches of disorder are indicated by thick black horizontal 
lines. The N-terminal portion of CTDSPL2 is significantly more disordered than 
CTDSPL. Truncations induced by viral integrations are indicated by a vertical black line. 
In both CTDSPL and CTDSPL2, the truncations remove a portion of the predicted 
disordered region. For CTDSPL2, the truncation also removes a predicted nuclear 
localization signal (NLS). For reference the catalytic domain (blue box) and NLS (green) 


























CTDSPL and CTDSPL2 induce expression changes in genes implicated in cellular 
migration, translation, alternative splicing and oxidative phosphorylation   
 To better characterize the role of CTDSPL and CTDSPL2 in ALV-induced B-cell 
lymphomas, we generated truncated transcripts in viral vectors to mimic those being 
expressed in tumors. Chick embryo fibroblasts (CEF) were infected with retroviral 
vectors (RCAS(A)) carrying either the truncated or full-length transcript of either 
CTDSPL or CTDSPL2. Transcripts were overexpressed approximately 100-fold relative 
to wild type CEF expression. 
Both CTDSPL and CTDSPL2 are believed to act on the CTD of RNA polymerase 
II to regulate gene expression (Yeo et al., 2003). We reasoned that overexpression of 
these genes by viral integration may be affecting downstream gene expression. To 
identify changes in gene expression, RNA-seq analysis was performed on cells 
overexpressing truncated or full length CTDSPL or CTDSPL2. Cufflinks (Trapnell et al., 
2012) was used to detect genes differentially expressed in cells carrying a CTDSPL or 
CTDSPL2 construct relative to cells infected with an empty retroviral construct. 
 We observed between 4 and 30 genes differentially expressed in each condition 
(Figure 5.5, Table 5.3). There was very little overlap in differentially expressed genes 
between overexpression conditions. MMP9, or matrix metalloproteinase-9 is the only 
gene that was significantly deregulated by overexpression of all constructs.  Cells 
expressing full length CTDSPL or CTDSPL2 had the most similar changes in gene 
expression profiles with approximately 1/3 of the deregulated genes overlapping between 




In order to determine differences in gene regulation induced by truncation of 
CTDSPL or CTDSPL2 genes we performed a GO analysis of genes differentially 
expressed between the full length and truncated form of both CTDSPL and CTDSPL2 
separately (Table 5.2; Table 5.4). Differentially regulated genes between truncated and 
full length CTDSPL were enriched for genes involved in mitochondria, oxidative 
phosphorylation, alternative splicing and Sp1 targets. Mitochondrial genes as well as 
genes involved in oxidative phosphorylation were found to be upregulated in the cells 
expressing truncated CTDSPL. Sp1 target genes and genes involved in alternative 
splicing were found to be downregulated in cells expressing the truncated construct.   
 In both cases an enrichment of genes involved in cellular locomotion or focal 
adhesion, E2F targets and ribosomal genes were observed. There was no clear trend of 
upregulation or downregulation of the genes in these GO categories. There was little 
overlap in affected genes between full length and truncated constructs. Expression of 
truncated CTDSPL or CTDSPL2 induced fewer changes in gene expression than either 















Figure 5.5: Genes differentially expressed by overexpression of CTDSPL or 
CTDSPL2 full length or truncated transcripts. RNA-seq analysis of CEF cells 
overexpressing truncated or full length CTDSPL or CTDSPL2 revealed a number of 
significantly overexpressed genes. Venn diagram depicting deregulation of gene 
expression by overexpression of truncated or full length CTDSPL or CTDSPL2. Genes 
shown in green were significantly upregulated relative to cells infected with an empty 
viral vector. Genes shown in red were significantly downregulated. Fold change in 





GO term P-value 
Enrichment in genes upregulated in TR1 vs. FL1 
Metabolism 0.00000125 
Oxidative phosphorylation 0.00000301 
Ribosome 0.000927 
Adherens/anchoring junctions 0.00471 
Factor: E2F 0.00997 




Factor: ETF 0.00000002 
Factor: Sp1 0.00000026 
Factor: E2F-3 0.00000897 
Cell migration 0.000286 
Alternative splicing 0.0000654 
Enrichment in genes upregulated in TR2 vs. FL2 
Ribosome 0.046 
Cell adhesion 0.05 
Enrichment in genes downregulated in TR2 vs. FL2 
Focal adhesion 0.0062 
Ribsomal protein 0.0157 
 
Table 5.2: Gene ontology (GO) analysis of genes differentially regulated by 





CTDSPL or CTDSPL2 expression induces cell migration in vitro 
 Due to the enrichment of genes involved in migration, such as MMP9, we next 
looked at whether cells overexpressing full length or truncated CTDSPL or CTDSPL2 had 
any differences in ability to migrate. To do this, we made use of a wound healing assay, 
or scratch assay, in which a confluent plate of CEF cells was scratched to disrupt the 
monolayer. At subsequent times after inflicting the “wound”, cells were imaged to 
visualize cell migration (Figure 5.6A). We observed that cells expressing either full 
length or a truncated CTDSPL or CTDSPL2 transcript had a significantly higher rate of 
cell migration compared to an empty vector control.  
 Cells migrating into the wound were quantified, and percent wound closure was 
calculated (Figure 5.6B). CTDSPL2 full-length overexpression had the largest effect with 
25% wound closure compared to just 5% closure seen in the empty vector control (p < 
0.0001). The truncated form of CTDSPL2 had a more modest effect with 18% closure 
observed on average (p < 0.0001; Figure 5.6B). Cells expressing CTDSPL truncated and 












Figure 5.6: CTDSPL and CTDSPL2 promote cellular migration in chick embryo 
fibroblasts. (A) A scratch assay was performed to monitor cell migration. Representative 
images of scratches at time 0 and at 8 hours are shown. (B) Quantification of wound 
closure. On average, uninfected CEF and CEF infected with empty viral vector exhibit 
approximately 5% wound closure after 8 hours. Cells expressing truncated CTDSPL2 
(TR2) exhibited significantly faster cellular migration rates with 18% wound closure on 
average after 8 hours (p < 0.0001). Cells expressing full length CTDSPL2 (FL2) had the 
fastest migration with 25% wound closure at the final time point (p < 0.0001). Cells 
overexpressing CTDSPL truncated and full-length (TR1, FL1) transcripts had 





CTDSPL2 overexpression prevents apoptosis induced by oxidative stress 
 Promotion of cell migration by CTDSPL and CTDSPL2 overexpression was 
observed when either truncated or full-length transcripts were expressed. Thus, this 
function does not explain why viral integrations that induce truncations were selected for 
in the tumors that we analyzed. Integrations in genes may also be selected for because 
they promote survival. To determine if integrations in CTDSPL and CTDSPL2 are 
affecting survival, we induced apoptosis in cells expressing either full length or truncated 
CTDSPL or CTDSPL2 by hydrogen peroxide treatment and measured cell death. 
Interestingly after 48 hours, cells expressing truncated or full length CTDSPL2 had 
significantly higher survival rates than cells expressing CTDSPL or empty vector control. 
CEF cells expressing either form of CTDSPL2 had approximately 3-fold higher survival 

















Figure 5.7: CTDSPL2 protects cells from apoptosis in vitro. Chick embryo fibroblasts 
were treated with hydrogen peroxide to induce apoptosis and survival was measured 
relative to cells infected with an empty viral vector. Expression of either full-length or 
truncated CTDSPL (FL1, TR1) provided no protection from apoptosis (p < 0.05). Cells 
expressing either truncated or full length CTDSPL2 (TR2, FL2) showed an approximately 







Overexpression of truncated viral fusion CTDSPL or CTDSPL2 transcripts promotes 
immortalization of primary cells in culture 
 The typical lifespan of primary chicken embryo fibroblasts in culture is 
approximately 30 days. After this point, proliferation of CEF cells as well as ALV-
infected CEF cells decreases dramatically. Overexpression of either full length CTDSPL 
or CTDSPL2 did not affect proliferation at later time points. In contrast, cells 
overexpressing the viral fusion transcripts of CTDSPL and CTDSPL2 did not undergo 
senescence (Figure 5.8). These cells continued proliferating at the same rate that was 
observed at earlier time points (data not shown). This effect of the truncated products on 
immortalization is likely the reason integrations were selected for in our initial screen of 





























Figure 5.8: Overexpression of truncated CTDSPL and CTDSPL2 promotes 
immortalization of primary cells in culture. Proliferation data shown is from day 42 to 
day 53 after infection. (A) Representative growth curve of CEF cells infected with virus, 
truncated or full length CTDSPL or CTDSPL2. (B) Average growth curve of three 
biological replicates. CEF cells as well as cells infected with empty virus stop 
proliferating at later time points. Cells overexpressing full length CTDSPL or CTDSPL2 
(FL1, FL2) proliferate less on average than uninfected CEFs. However, cells 
overexpressing truncated viral fusion transcripts of either CTDSPL or CTDSPL2 (TR1, 
TR2) exhibit significantly higher proliferation at later time points indicating that they 






Figure 5.9: Summary of findings. Overexpression of the truncated viral fusion 
transcripts of CTDSPL and CTDSPL2 promote immortalization in primary cell culture. 
Expression of either full length or truncated CTDSPL2 protected cells from apoptosis. 












In this report we have identified both CTDSPL and CTDSPL2 as common 
integration sites in ALV-induced B-cell lymphomas. In addition to being common 
integration sites, a large number of integrations in these genes were clonally expanded, 
suggesting a role in tumorigenesis. Further evidence for a driving role in cancer is 
suggested by the presence of identical integrations in primary and secondary tumors 
within the same bird. This indicates that these integrations were likely an early event in 
the development of cancer within these birds.  
We show that viral integrations in CTDSPL and CTDSPL2 were driving the 
overexpression of a truncated transcript. Overexpression of CTDSPL and CTDSPL2 
caused changes in the expression of genes involved in cellular migration, most notably 
MMP9, which was upregulated by overexpression of all constructs. Correspondingly, we 
observed an increase in cellular migration rates in cells overexpressing truncated and full-
length transcripts. This, in addition to the observation that integrations in CTDSPL and 
CTDSPL2 occur in both primary and secondary tumors, suggests a potential role in 
promoting tumor metastasis. While CTDSPL2 is not well studied, it has been 
demonstrated to play a role in bone morphogenetic protein (BMP) signaling through 
dephosphorylation of Smad proteins (Zhao et al., 2014). This has been shown to strongly 
promote cell migration in hepatocellular carcinoma cell lines (Maegdefrau and 
Bosserhoff, 2012). Further, inhibition of BMP signaling suppressed metastasis in 
mammary cancer (Owens et al., 2015). This role of CTDSPL and CTDSPL2 in cellular 
migration agrees with previously published data that CTDSP1/2/L proteins promote 




et al., 2009). The promotion of cellular migration appears to be a gain of function due to 
overexpression of the CTDSPL and CTDSPL2 transcripts. 
The overexpression of truncated viral fusion transcripts of both CTDSPL and 
CTDSPL2 promotes immortalization of primary cells in culture. This is a feature unique 
to the truncated transcripts, as overexpression of full-length forms of both genes did not 
significantly improve proliferation rates at times past the normal lifespan of CEFs. We 
believe that this role in immortalization is likely the reason that integrations promoting 
the expression of truncated forms of both genes are selected for in ALV-induced B-cell 
lymphomas. This role in immortalization for CTDSPL and CTDPSL2 is interesting to 
note due to the co-occurrence of CTDSPL and CTDSPL2 integrations with integrations 
into TERT, which has previously been reported to promote immortalization (Bodnar et 
al., 1998). 
CTDSP1/2/L are fairly well characterized genes that have been repeatedly shown 
to play partially redundant roles. CTDSPL2 seems to be fairly similar to the other 
members of the CTDSP family in many regards. Some functions are known to overlap, 
such as regulation of BMP signaling. Here we show that CTDSPL2 promotes metastasis 
similar to CTDSPL. These overlapping functions, in addition to the observation that 
despite integrations in both genes, only one is overexpressed in individual tumors, would 
suggest that CTDSPL and CTDSPL2 might be redundant. However, we observed that 
expression of CTDSPL2, and not CTDSPL, can protect cells from apoptosis induced by 
oxidative stress. 
CTDSPL2 does have distinct features from the other members of the CTDSP 




family. No intronic microRNA has been reported in CTDSPL2. The CTDSPL2 protein, at 
53 kDa, is significantly larger in size than CTDSP1/2/L proteins, which all weigh in at 
around 32 kDa on average. Each protein in the family contains a C-terminal phosphatase 
domain, but CTDSPL2 has significantly more N-terminal sequence of unknown function. 
The N-terminal region that is truncated in the viral fusion transcript is predicted to be 
intrinsically disordered (Figure 5.4B). Likewise, the truncated portion of CTDSPL is also 
predicted to be partially disordered. Given that the CTD of RNA polymerase II has been 
shown to associate with proteins with low-complexity domains, it is possible that these 
disordered regions are in part responsible for binding of CTDSPL and CTDSPL2 to the 
CTD. Thus, in the truncated transcript that is expressed in tumors, these proteins may not 
be able to associate with RNA polymerase II or other substrates.  
Furthermore, unlike CTDSP1/2/L proteins, CTDSPL2 has not been previously 
reported to act on pRb, a main tumor suppressor target common to the other 3 members 
of the family. However, in our RNA-seq analysis, nearly 75% of the genes that were 
differentially expressed by 2-fold or more in cells overexpressing CTDSPL2 were E2F 
target genes. E2F is a transcription factor targeted by pRb. When pRb is 
dephosphorylated and thus active, it binds E2F, keeping it inactive. Once pRb becomes 
phosphorylated in G1, it releases E2F allowing it to act on downstream effector genes 
causing the transition from G1 to S phase (Polager and Ginsberg, 2008). CTDSP1/2/L 
were shown to dephosphorylate and thus activate pRb (Zhu et al., 2012b) . Due to 
regulation of E2F target genes by CTDSPL2, it seems likely that this protein may also act 




Our work suggests that CTDSPL and CTDSPL2 play a role in cancer and seem to 
have pro-oncogenic characteristics (Figure 5.9). Expression of either of these genes 
promotes metastasis in cell culture and CTDSPL2 protects cells from apoptosis. Neither 
of these functions is affected by the viral truncation. We believe that the main reason 
integrations in CTDSPL and CTDPSL2 were selected for in B-cell lymphomas is due to 
the role of the truncated transcripts in immortalization. We hypothesize that the gene 
truncations imposed by the viral integrations in tumors remove a region of the protein 
that is responsible for interaction with pRb. The truncated proteins would no longer be 
able to dephosphorylate pRb and would potentially lose their tumor suppressor function. 
Genes deregulated by expression of the truncated transcript were also enriched in 
downstream effectors and processes of the pRb pathway, such as E2F and Sp1 target 
genes (Polager and Ginsberg, 2008). This suggests that the truncated version of the 
proteins interact with pRb differently causing a change in expression of downstream 
effectors of pRb. We hypothesize that the removal of a portion of a predicted intrinsically 
disordered region may inhibit these proteins from interacting with its normal protein-
binding partners. For CTDSPL2, the truncation also removes a nuclear localization signal 
that may prevent the protein from reaching the nucleus. pRb has been shown to be a 
dominant effector of cellular senescence with inactivation of pRb delaying onset of 
cellular senescence (Campisi, 2005; Haferkamp et al., 2009). If the truncated CTDSPL 
and CTDSPL2 proteins can no longer activate pRb through dephosphorylation, then pRb 
may become phosphorylated and thus inactive, allowing for evasion of senescence as 













CTDSPL virus  fl1 76.78 17615.00 7.84 0.01 
IGFBP4 virus  fl1 97.05 344.36 1.83 0.01 
PHLDA2 virus  fl1 848.26 2464.20 1.54 0.01 
WDR24 virus  fl1 31.34 117.73 1.91 0.01 
HSPB1 virus  fl1 453.66 1323.48 1.54 0.01 
CLIC2 virus  fl1 77.73 245.47 1.66 0.01 
RPLP1 virus  fl1 1633.35 4518.34 1.47 0.01 
MMP9 virus  fl1 66.67 203.62 1.61 0.01 
GPX3 virus  fl1 230.60 638.03 1.47 0.01 
PRRX1 virus  fl1 402.33 983.46 1.29 0.01 
ACTG2 virus  fl1 602.16 1497.56 1.31 0.01 
RPS29 virus  fl1 1852.45 4731.70 1.35 0.01 
THY1 virus  fl1 1222.43 3083.13 1.33 0.01 
TLN1 virus  fl1 62.13 148.89 1.26 0.01 
PPDPF virus  fl1 337.37 882.52 1.39 0.01 
HSPG2 virus  fl1 32.95 78.14 1.25 0.01 
RPS15 virus  fl1 2775.50 6422.73 1.21 0.01 
LMF2 virus  fl1 216.30 502.87 1.22 0.01 
CTSK virus  fl1 175.35 443.76 1.34 0.02 
CCDC101 virus  fl1 141.08 337.39 1.26 0.02 
BCL2L1 virus  fl1 166.00 436.28 1.39 0.02 
OST4 virus  fl1 2030.88 5113.26 1.33 0.02 
TUBB virus  fl1 450.43 966.51 1.10 0.02 
FGFR1 virus  fl1 60.02 141.34 1.24 0.03 
HSP90B1 virus  fl1 494.94 239.69 -1.05 0.04 
HIC1 virus  fl1 38.04 101.29 1.41 0.04 
ACTN4 virus  fl1 86.34 205.06 1.25 0.04 
G0S2 virus  fl1 275.39 691.71 1.33 0.04 
CXCL14 virus  fl1 302.04 635.73 1.07 0.04 
CEBPB virus  fl1 63.24 192.42 1.61 0.04 
CTDSPL virus  tr1 79.02 7386.97 6.55 0.04 
OST4 virus  tr1 2089.22 6399.39 1.61 0.04 
RPLP1 virus  tr1 1680.51 5375.79 1.68 0.04 
MMP9 virus tr1 82.64 155.26 0.91 0.04 
BRD2 virus  fl2 96.89 244.08 1.33 0.01 
CD99 virus  fl2 264.15 641.17 1.28 0.01 
CXCL14 virus  fl2 316.59 634.03 1.00 0.01 
DAG1 virus  fl2 72.18 180.77 1.32 0.01 




HIC1 virus  fl2 39.87 116.75 1.55 0.01 
HSPB1 virus  fl2 475.54 1263.80 1.41 0.01 
HSPG2 virus  fl2 34.53 84.45 1.29 0.01 
IGFBP4 virus  fl2 101.73 373.23 1.88 0.01 
MMP9 virus  fl2 69.88 210.86 1.59 0.01 
OST4 virus  fl2 2128.86 5479.19 1.36 0.01 
PHLDA2 virus  fl2 889.13 1754.00 0.98 0.01 
RPLP1 virus  fl2 1712.10 3737.50 1.13 0.01 
TLN1 virus  fl2 65.12 134.75 1.05 0.01 
TUBB virus  fl2 472.14 1302.85 1.46 0.01 
CTDSPL2 virus  fl2 60.90 5416.11 6.47 0.01 
LRP1 virus  fl2 113.33 214.77 0.92 0.01 
TIMP2 virus  fl2 1532.28 3064.68 1.00 0.01 
THY1 virus  fl2 1281.35 2382.98 0.90 0.02 
TNS1 virus  fl2 58.86 118.23 1.01 0.02 
ELL virus  fl2 18.57 56.76 1.61 0.03 
RPS29 virus  fl2 1941.83 3992.96 1.04 0.03 
SLC9A1 virus  fl2 51.29 128.46 1.32 0.04 
LOC395160 virus  fl2 7591.35 4226.02 -0.85 0.04 
SP1 virus  fl2 29.98 95.87 1.68 0.04 
CD99 virus  tr2 257.15 894.19 1.80 0.02 
CTDSPL2 virus  tr2 59.27 6472.04 6.77 0.02 
MMP9 virus  tr2 68.05 204.13 1.58 0.02 
THY1 virus  tr2 1247.71 2585.62 1.05 0.02 
TMSB4X virus  tr2 22900.10 10839.20 -1.08 0.02 
TUBB virus  tr2 459.79 1019.54 1.15 0.02 
G0S2 virus  tr2 281.09 908.97 1.69 0.02 
LRP1 virus  tr2 110.33 242.59 1.14 0.02 
APOA1 virus  tr2 170.46 479.51 1.49 0.03 
 
Table 5.3: Cuffdiff results comparing gene expression in cells expressing either 
truncated or full length CTDSPL or CTDSPL2 relative to cells infected with an 
empty viral vector. Each sample is compared relative to cells infected with an empty 







GO term P-value Genes 




PSMB1, MGST1, MSMO1, OAT, ASNS, RPL31, NUP37, 
NDUFB2, PSMA6, SQLE, PPP2CB, PRKAG2, RPL34, 
NDUFA8, RPL5, AMD1 ,UQCR11, PAICS, DCTD, 
COX4I1, RAN, NDUFB5, HADH, LBR, RPL37, GSTO1, 
ATP5G3, CMPK1, HPGDS, RPL22L1, STARD4, 
CYB5A, IDH3A, ACAA2, UQCRFS1, SLC25A6, BPGM, 






NDUFB2, NDUFA8, UQCR11, ATP6V1E1, COX4I1, 





MRPS35, RPL31, RPL34, MRPS14, RPL5, RPL37, 




RPL31, CHMP2B, RPL34, PRDX1, RPL5, PAICS, RAN, 
RRAS2, ACTR2, ITGAV, G3BP1, TWF1, CCT8, 
ANXA5, RPL38, RPL12 
Factor: E2F 0.00997 
PSMB1, GLT8D1, MSMO1, MRPS35, OAT, RPL31, 
WDR1, SLC25A3, PREP, NDUFB2, TXN2, PSMA6, 
PGRMC1, RP2, SQLE, PPP2CB, PRKAG2, UFSP2, 
TMEM30A, USP4, PRDX1, STMN1, UCHL3, NDUFA8, 
UFM1, TBC1D15, SPRYD7, AMD1, UQCR11, PAICS, 
DCTD, LSM7, ATP6V1E1, COX4I1, CHMP1A, RAN, 
TPT1, SLC38A2, CDC73, MPHOSPH6, ATP6V1G1, 
ACTR2, ITGAV, HADH, NEDD1, TSPAN3, CDR2, 
LBR, RPL37, G3BP1, GSTO1, N6AMT2, TWF1, 
UCHL1, VMA21, CMPK1, MEMO1, HPGDS, ATP1A1, 
SLMAP, H2AFZ, ANXA5, STARD4, VDAC2, CYB5A, 
IDH3A, PHB, SNRPD1, CRK, ACAA2, UQCRFS1, 
SLC25A6, ARL6IP1, RNF139, RAB33B, BPGM, RPL38, 
UQCRH, AP3S1, MCFD2, ALDH1A3, YTHDF3, GMFB, 
FAR1, CAPZA2, TMSB4X, VDAC1, MRPS17 






CD99, ITGA3, PPP1R12A, PABPC1, TNS1, PPFIBP1, 
PTK7, LRP1, FLOT2, RAC1, TLN1, GIT2, HSPG2, 





CD99, ITGA3, LAMP2, MAP2K3, TIMP2, VCAN, 
FAM214A, MRTO4, PPP1R12A, HDAC7, WAPAL, 
NAV3, MEF2A, PABPC1, NDE1, PTGS2, FGFR1, 
SMARCA2, TDRD3, AK6, CCNK, FKBP5, KDELR3, 
CHMP4B, NDFIP2, TSC22D1, FAM173A, SF3A2, 
MEOX2, RSRC2, ELK3, CPSF6, RWDD1, PTK7, IK, 
CISH, NCL, SPTBN1, HPCAL1, PRRX1, B4GALT2, 
PRDX6, EGR1, CLU, LRP1, G0S2, STAU1, PPDPF, 




PUM1, FADS2, RAC1, TLN1, ETV6, GIT2, MFAP1, 
PARN, IGFBP4, COL6A1, COL6A2, HSPG2, RIT1, 
SNRNP200, METTL21A, CTDSPL, ADPRH, CCNA2, 
SFRP2, CXCL14, ADD3, ADAM33, HNRNPDL, CFDP1, 
THY1, ELMO1, EIF5B, RNF166, ZYX, RPL8, PPAP2B, 
ZNF326, PM20D1, RPRD2, CDCA7L, ARF6, TAF3, 
MAPRE2, LINGO1, SIX2, PDGFD, CANT1, HDAC3, 
PTPN2, YES1, BASP1, PTRF, PHLDA2, PRKAG1, 
COL18A1, EWSR1, TOP1MT, PDE4B, SP1, COL4A1, 





CD99, ITGA3, LAMP2, MAP2K3, TIMP2, VCAN, 
FAM214A, PPP1R12A, HDAC7, NAV3, MEF2A, 
PABPC1, NDE1, FGFR1, TNS1, SMARCA2, AK6, 
CCNK, FKBP5, KDELR3, CHMP4B, NDFIP2, 
TSC22D1, FAM173A, SF3A2, CBLL1, PPFIBP1, 
RSRC2, ELK3, CPSF6, PTK7, IK, CISH, NCL, SPTBN1, 
HPCAL1, PRRX1, B4GALT2, PRDX6, DUSP1, EGR1, 
CLU, CDK2, LRP1, STAU1, PPDPF, WDR44, 
SERPINF1, FLOT2, NES, MYH10, SRRM1, BHLHE40, 
FADS2, RAC1, TLN1, ETV6, MFAP1, MFGE8, PARN, 
IGFBP4, COL6A1, COL6A2, HSPG2, RGL1, RIT1, 
SNRNP200, METTL21A, CTDSPL, ADPRH, CCNA2, 
SFRP2, CXCL14, ADD3, ADAM33, HNRNPDL, CFDP1, 
THY1, EIF5B, RNF166, RUNX1, ZYX, RPL8, PPAP2B, 
ZNF326, PM20D1, RPRD2, ARF6, MAPRE2, ADAM9, 
UGP2, LINGO1, SIX2, PDGFD, CANT1, BCL2L1, 
HDAC3, PTPN2, YES1, CCDC101, BASP1, PTRF, 
PHLDA2, PRKAG1, COL18A1, EWSR1, TOP1MT, 
PDE4B, SP1, COL4A1, NOC2L, H1F0, SUPT5H, SRC, 




CD99, ITGA3, LAMP2, MAP2K3, TIMP2, VCAN, 
FAM214A, HDAC7, WAPAL, NAV3, MEF2A, PABPC1, 
NDE1, FGFR1, SMARCA2, TDRD3, AK6, CCNK, 
FKBP5, KDELR3, CHMP4B, TSC22D1, FAM173A, 
SF3A2, PPFIBP1, ELK3, CPSF6, PTK7, IK, CISH, NCL, 
SPTBN1, HPCAL1, PRRX1, B4GALT2, PRDX6, 
DUSP1, EGR1, CLU, CDK2, LRP1, STAU1, PPDPF, 
WDR44, SERPINF1, FLOT2, NES, MYH10, SRRM1, 
BHLHE40, FADS2, RAC1, TLN1, ETV6, MFAP1, 
MFGE8, PARN, IGFBP4, COL6A1, COL6A2, HSPG2, 
RGL1, RIT1, METTL21A, CCNA2, ADD3, ADAM33, 
HNRNPDL, CFDP1, THY1, ELMO1, RNF166, RUNX1, 
ZYX, RPL8, ZNF326, PM20D1, RPRD2, CDCA7L, 
ARF6, TAF3, MAPRE2, ADAM9, UGP2, LINGO1, 




CCDC101, BASP1, PTRF, NQO1, PHLDA2, PRKAG1, 
COL18A1, EWSR1, TOP1MT, SP1, COL4A1, NOC2L, 





ITGA3, HDAC7, NDE1, PTGS2, FGFR1, TNS1, CBLL1, 
MEOX2, ARHGDIB, PTK7, LRP1, SERPINF1, MYH10, 
RAC1, SFRP2, CXCL14, THY1, ELMO1, PPAP2B, 
ADAM9, SIX2, PDGFD, YES1, PHLDA2, COL18A1, 





TSC22D1, LAMP2, LRP1, CTDSPL, COL6A2, 
PPP1R12A, PUM1, VCAN, BCL2L1, SRC 
Enrichment in genes upregulated in TR2 vs. FL2 
Ribosome 0.046 RPS2, MRPL33, RPS3 
Cell adhesion 0.05 RPS2, MRPL33, RPS3 
Enrichment in genes downregulated in TR2 vs. FL2 
Focal adhesion 0.0062 CAV1, RPS29, RPLP1, DAG1, CAPN2 
Ribsomal 
protein 
0.0157 MRPS26, RPLP1, MRPL20 
 
Table 5.4: Detailed gene ontology (GO) information. GO terms that were enriched for 
genes up- or downregulated in cells overexpressing the truncated form of the gene versus 
















































Nehyba J.*, Malhotra S.*, Winans S.*, O’Hare T, Justice J. 4
th
, Beemon K. (2016). 
Avian leukosis virus activation of an antisense RNA upstream of TERT in B-cell 
lymphomas. J Virol. 90(20):9509-17. 












Avian leukosis virus (ALV) induces tumors by integrating its proviral DNA into 
the chicken genome and altering expression of nearby genes via strong promoter and 
enhancer elements. Viral integration sites that contribute to oncogenesis are selected in 
tumor cells. Deep sequencing analysis of B-cell lymphoma DNA confirmed that the 
telomerase reverse transcriptase (TERT) promoter is a common ALV integration target. 
Twenty-six unique proviral integration sites were mapped between 46 and 3552 nt 
upstream of the TERT transcription start site, predominantly in the opposite 
transcriptional orientation of TERT. RNA-seq analysis of normal bursa revealed a 
transcribed region upstream of TERT in the opposite orientation, suggesting the TERT 
promoter is bidirectional. This transcript appears to be an uncharacterized antisense RNA 
which we have named TAPAS (TERT antisense promoter associated) RNA.  We have 
previously shown that TERT expression is up regulated in tumors with integrations in the 
TERT promoter region.  We now report that the viral promoter drives expression of a 
chimeric transcript, containing viral sequences spliced to exons 4 through 7 of this 
antisense RNA. Clonal expansion of cells with ALV integrations driving over expression 
of this TERT antisense RNA suggest it may have a role in tumorigenesis. Functional 
analysis of the TAPAS RNA transcript reveal that it plays a role in regulating TERT 
mRNA expression in chickens. We also find evidence of a similar transcript in humans 










High throughput sequencing revealed multiple integration sites in a series of 
rapid-onset ALV-induced B-cell lymphomas (6). The TERT promoter region was 
identified as the most clonally expanded of these integrations, suggesting this is an early 
event in tumorigenesis (Justice et al., 2015b).  Twenty-six unique integration sites were 
identified in this region in multiple independent tumors (Justice et al., 2015b).  
Telomerase is a ribonucleoprotein complex that adds repeat sequences to 
chromosome ends. It contains a catalytic protein component, TERT, as well as a non-
coding telomerase RNA template component (TERC). Elevated telomerase activity has 
been detected in more than 90% of all human cancers (Shay and Wright, 2011). In 
addition, many human tumors have a point mutation in the TERT promoter at -124 or -
146 nt upstream of the TERT translation start site (Heidenreich et al., 2014). These 
mutations up-regulate TERT expression (Borah et al., 2015; Horn et al., 2013; Huang et 
al., 2013; Killela et al., 2013). Elevated telomerase activity maintains telomere lengths 
and prevents apoptotic signaling, thus allowing continual proliferation and long-term 
viability of cancer cells (Blasco, 2005). It has also been shown that TERT can promote 
oncogenesis independent of the reverse transcriptase function of telomerase (Koh et al., 
2015).  
Telomerase activity in most somatic cells is limited by the availability of TERT 
protein, and expression of TERT is tightly regulated at the transcriptional level through 
epigenetic modifications in the promoter region (Delany and Daniels, 2004; Zhu et al., 
2010). In addition, extensive alternative splicing of the TERT transcript has been shown 




Saebøe-Larssen et al., 2006; Withers et al., 2012).  Both human and chicken telomerase 
expression is down regulated in most normal somatic tissues (Collins and Mitchell, 2002; 
Taylor and Delany, 2000). Furthermore, human and chicken telomeres shorten with age, 
and telomerase activity is important for oncogenesis (Delany et al., 2000). In contrast, 
mice express telomerase in normal somatic cells and have longer telomeres than humans 
or chickens (Hackett and Greider, 2002).  Therefore, chicken serves as a good model to 
study oncogenic events of TERT activation and signaling.      
We previously reported that ALV integrations upstream of TERT cause a 2-4 fold up-
regulation of TERT expression in rapid-onset B-cell lymphomas (Yang et al., 2007b). 
However, these integrations were in the opposite transcriptional orientation to TERT, 
unlike most previously characterized common integration sites in ALV-induced tumors 
(Clurman and Hayward, 1989; Hayward et al., 1981; Kanter et al., 1988). In this work, 
we show that these integrations also drive over-expression of a novel antisense transcript, 
associated with the bidirectional TERT promoter, which we call TAPAS (TERT Antisense 
Promoter ASsociated) RNA.  The ALV integrations result in chimeric transcripts with 
ALV leader sequences spliced into exon 4 of the 7-exon TAPAS RNA. Knockdown of 
this transcript causes a concordant decrease in TERT mRNA expression in primary chick 
embryo fibroblasts. Overexpression of TAPAS had little effect on TERT expression 
indicating that TAPAS is likely regulating TERT in cis. 
 Analysis of RNA-seq data revealed the presence of a transcript in humans in the 
same region of the TERT promoter. Using RT-PCR, we characterized a 1.6 kb transcript 
170 nt upstream of the TERT transcription start site. It is an unspliced transcript and also 




knockdown of this hTAPAS transcript in HEK293T cells causes an increase in TERT 
mRNA expression. In agreement, analysis of cancer transcriptome data from various 

























TERT promoter is a common ALV integration site in B-cell lymphomas 
In order to identify genes contributing to the formation of ALV-A induced rapid-
onset B-cell lymphomas, high throughput sequencing of proviral – host DNA junctions 
was previously performed (Justice et al., 2015b). Common integration sites in the host 
genome that contribute to tumorigenesis are present in multiple tumor cells and thus are 
overrepresented in the deep sequencing data. The TERT promoter region was identified 
as the most clonally-expanded, common integration site  with integrations present in 
seven different lymphomas from five birds (Figure 6.1A).  We analyzed 19 of the most 
clonally expanded, unique integrations from both primary bursal tumors (B) and tumors 
metastasized to the liver (L). Three of the clonally expanded integrations were present in 
multiple tissues from the same bird. The integration sites ranged from 46 nt to 3552 nt 
upstream of the TERT transcription start site. The majority of the proviral integrations 
(16/19) were in the opposite transcriptional orientation to TERT. Four out of 7 
lymphomas, termed C7B, C6L, C7L, and D2L had integrations only in the opposite 
orientation. The remaining three tumors – A1B, C2B, and C2L – harbored integrations in 
the same orientation as TERT, but also contained integrations in the opposite orientation 
that were more clonally expanded. In contrast, no integrations in the TERT promoter 
region were identified in any non-tumor tissues of infected birds (Figure 6.1B). The 
observation of proviral integrations in this region in multiple tumors suggests that ALV 





Figure 6.1: The TERT promoter region is a common site of ALV proviral 
integration in lymphomas. (A) Schematic of the most clonally expanded ALV 
integration sites near TERT in 7 tumors, shown with the first 3 exons of the TERT gene. 
Tumor names correspond to the bird and tissue in which the tumor was collected. All of 
the integrations clustered within 3.5 kb upstream of the TERT transcriptional start site. 
Integrations are predominantly in the opposite orientation (red) with respect to TERT 






Novel antisense (TAPAS) RNA is transcribed from TERT bidirectional promoter  
In order to assess the effects of proviral integrations on host gene expression, deep 
sequencing of the transcriptome of selected ALV-induced lymphomas and normal bursa 
controls was performed. This analysis revealed a 9 kb transcribed region upstream and in 
the opposite transcriptional orientation of TERT in the normal bursa controls (Figure 
6.2A). This suggests that the TERT promoter is bidirectional. With the use of TopHat 
bioinformatics tools, a number of putative introns were identified and confirmed by 
sequence analysis of exon junctions. This analysis suggested a 3.6 kb spliced transcript, 
containing 7 exons.  RT-PCR studies confirmed 2.2 kb of this transcript containing exons 
1 through 7 (Figure 6.2A). RT-PCR experiments were not able to amplify the last 1050 nt 
of exon 7. Two putative poly(A) sites were identified by 3’RACE at positions 1051 and 
1114 of exon 7.  
Strand-specific RNA-seq data indicates that the first exon of TERT and the 
associated bidirectional transcript overlap (Figure 6.2A). RT-PCR verified that at least 
the first 161 nt of TERT exon 1 are shared with TAPAS RNA. It is possible that more of 
exon 1 is shared between the two genes; however, this could not be confirmed by RT-
PCR, likely due to the high GC content of TERT exon 1. Additionally, a number of 
alternatively spliced transcripts were detected, including some skipping exon 2 and others 
skipping both exons 2 and 3 (Figure 6.2B).  
There is a small open reading frame (ORF) (258 nt) that spans exons 4 and 5 and 
two longer ORFs, of 408 and 375 nts, present in exon 7. However, one of these ORFs is 
located within the unverified region at the 3’ end of the transcript, beyond the main 




poorly conserved between most avian species (data not shown). Moreover, no protein 
domain homology was observed in any region of the transcript (Marchler-Bauer et al., 
2014), implicating this transcript as a putative long non-coding RNA (lncRNA).  
The recent release of the Gallus gallus 5 whole-genome assembly predicts an 
antisense transcript upstream of TERT (LOC107052651). The predicted transcript variant 
(XR_001465267.1) corresponds to exons 2 through 7 of TAPAS RNA (Figure 6.2A). 
This variant contains 643 nt more of exon 7 and does not share any sequence with TERT 
exon 1, unlike the transcript reported here. Another transcript variant with retention of an 
intron between our exons 2 and 3 is also predicted (XR_001465266.1).  Further, the 
NCBI eukaryotic gene prediction tool, Gnomon, annotates the predicted transcript as a 

















Figure 6.2: Schematic of TAPAS gene (A) Representative Bedgraph from normal bursa 
tissue shows normalized transcription coverage. Coverage on the plus and minus strands 
is colored green and blue, respectively. The primary transcript observed by RNA-seq in 
normal chicken bursa is approximately 9 kb. The principal form of the spliced transcript 
is 3.6 kb and contains 7 exons. Confirmed region of shared exon 1 is depicted in green-
blue stripes. A portion of exon 7 that could not be verified by RT-PCR is indicated in 
light blue. Transcripts confirmed by RT-PCR are 2-3 kb. The two main 3’ ends identified 
are indicated by vertical orange lines and are located at nucleotide 1051 and 1114 of exon 
7. (B) Multiple alternatively spliced variants of TAPAS RNA were also identified in 




TAPAS RNA expression is elevated in tumors with integrations in the TERT promoter 
The predominance of proviral integrations in the opposite orientation of TERT, as 
well as the identification of a bidirectional transcript, suggested that the integrations 
might also be driving increased expression of TAPAS RNA. To test this hypothesis, we 
performed quantitative reverse-transcription PCR (qRT-PCR) to determine TAPAS RNA 
expression levels in tumors containing integrations in the TERT promoter region (Figure 
6.3A). Normal liver has 148- and 5-fold less expression than normal bursa for TAPAS 
and TERT RNA, respectively. Compared to normal liver, tumors with integrations in the 
TERT promoter had significantly increased expression of the TAPAS RNA. Expression 
of the bidirectional TAPAS RNA was up-regulated approximately 250- to 3858-fold 
relative to normal liver tissue. In contrast, TERT was up-regulated 4- to 42-fold relative 
to normal liver tissue (Figure 6.3B). This suggests that the observed integrations in the 
TERT promoter are driving expression of a bidirectional lncRNA. These findings were 














Figure 6.3: Expression of TAPAS RNA and TERT in ALV-induced B-cell 
lymphomas. qRT-PCR was performed to determine (A) TAPAS RNA and (B) TERT 
expression in seven ALV induced tumors as well as normal bursa (NB) and normal liver 
(NL) controls. Expression of both transcripts is significantly higher in 5 of the 6 tumors 










Viral transcripts splice into exon 4 of TAPAS RNA 
Retroviruses can induce overexpression of host genes by multiple mechanisms 
(1,44). For instance, insertion of viral enhancer elements in the vicinity of host gene 
promoters can induce overexpression (Beemon and Rosenberg, 2012). Alternatively, the 
viral promoter can drive expression of the host gene directly, if both are in the same 
orientation, by readthrough of the viral poly(A) site (Kanter et al., 1988).  If the promoter 
in the viral 5’ LTR is driving expression, the viral RNA transcript can splice via the gag 
splice donor into the cellular mRNA (Kanter et al., 1988). Alternatively, if the promoter 
in the 3’ LTR is used, read-through into the adjacent host genomic region occurs 
(Hayward et al., 1981). To determine the mechanism by which proviral integrations are 
affecting TAPAS RNA expression, we analyzed metastasized tumors with integrations in 
the same transcriptional orientation as the TAPAS RNA. We performed RT-PCR using 
LTR specific primers and primers within the TAPAS RNA exons to obtain and sequence 
viral TAPAS RNA fused transcripts (Figure 6.4A). 
Proviruses in tumor D2L use the 5’ LTR to drive expression of TAPAS RNA. 
One splice variant used the canonical 5’ viral splice donor site in gag (nucleotide 398). 
Transcripts were also detected in which an alternative splice donor site in the viral gag 
gene (nucleotide 857) spliced into exon 4 of TAPAS RNA. In tumor C7L, a provirus 
integrated in intron 2 also spliced into exon 4 of TAPAS RNA from the canonical 5’ viral 
splice donor site.  
Alternatively, transcripts in which the viral 3’ LTR serves as the promoter were 
observed in tumor C6L. These transcripts contained 63 nucleotides of host DNA adjacent 




may be used to splice into the downstream exon 4.  Sequencing of the provirus C6L 
revealed a large deletion that included the viral splice donor site in gag (Figure 6.4B); 
this would prevent its splicing into the TAPAS RNA if it initiated in the 5’ LTR.  
However, this deletion would probably also prevent transcription initiation at the 5’ LTR, 
as previously observed with ALV integrations in MYC (Goodenow and Hayward, 1987).  
A similar 3’ LTR initiated transcript was observed from the C7L proviral integration in 
intron 1 of TAPAS RNA. This variant spliced from a cryptic splice donor site, 28 
nucleotides downstream of the provirus, into exon 4 of the TAPAS RNA.  
 The majority of proviral integrations are located between exon 1 and exon 4 of the 
TAPAS gene (Figure 6.4A). However, regardless of the integration site location, all of 
the viral transcripts analyzed invariantly spliced into exon 4 of the TAPAS RNA. For 
most of the viral transcripts, this means that nearby exons are skipped and splicing is 
preferentially occurring to exon 4.  While the 5’ spliced viral leader sequence contains a 
bit of the ALV gag gene, the analyzed chimeric transcripts have a termination codon 
before the AUG of the ORF in exon 4 of the TAPAS RNA.  Thus, no hybrid protein is 
predicted.  Consistent splicing into exon 4 suggests the possible functional importance of 









Figure 6.4: Viral RNAs splice into exon 4 of TAPAS RNA. (A) Splicing of viral 
transcripts was determined by RT-PCR of tumor RNA. All proviruses indicated in this 
figure are in the opposite transcriptional orientation of TERT. Arrows indicate genomic 
location of proviral integration. Despite the presence of upstream exons, all viral 
transcripts analyzed splice into exon 4 of the TAPAS RNA from either canonical gag 
splice donor (SD) or via alternate splice donor (ASD) sites. Read through transcription 
from 3’LTR is depicted by a red square. (B) Sequence analysis shows mutations in 
proviruses C6L and one of the C7L integrations. Three integrated proviruses, two in 
tumor C7L and one in tumor C6L were sequenced. The viral LTRs are depicted with 
white boxes at termini of viral genome with the U3, R and U5 direct repeats respectively. 
gag-pol are depicted in grey and env in black. The 1.2 kb deletion in C6L removes the 
canonical viral splice donor and induces transcription from the 3’LTR. Exon positions of 






















TAPAS RNA is expressed in normal chicken tissues and during development 
 To further characterize expression of the TAPAS RNA, we analyzed publicly 
available RNA-seq data sets from the SRA database (Leinonen et al., 2011). TAPAS 
RNA and TERT expression was measured in various chicken tissues of an 18 day 
embryo.  In addition, transcriptome of total embryos were analyzed at different time 
points up to 12 days of development (SRA Accession no. ERX697750 and DRX001564 
respectively) (Leinonen et al., 2011). Quantification of transcript expression was 
determined by calculating fragment count normalized to transcript length and total 
number of reads (FPKM). This analysis showed that the TAPAS RNA is expressed in 
some normal chick embryo tissues. TAPAS RNA is expressed at particularly high levels 
in bursa, testes and kidney and is undetectable in muscle and heart tissue (Figure 6.5A).  
TAPAS RNA expression was higher than TERT in bursa and testes but more comparable 
in other tissues and in total early embryos.   
 Furthermore, both TAPAS RNA and TERT expression is elevated early in chick 
development and progressively decreases with time (Figure 6.5B). Thus, the tissue 
specific and developmental expression of TAPAS RNA correlates with TERT expression. 
This suggests that the TAPAS RNA may have a role in regulating TERT expression or 










Figure 6.5: TERT and TAPAS RNA are expressed at comparable levels in adult 
tissues and during chick development. (A) RNA-seq data of expression of TAPAS 
RNA in normal 18 day chicken embryo tissues. TAPAS RNA is expressed in various 
tissues at levels similar to TERT. In bursa, TAPAS RNA expression is approximately 3-
fold higher than TERT. (Pearson correlation coefficient = 0.66, p = 0.07). (B) The 
expression of TERT and TAPAS RNA also seem to be correlated throughout 






TAPAS RNA is conserved 
 To determine if the novel TAPAS RNA is conserved, we performed phylogenetic 
analysis in multiple avian species. Exons 4, 5 and 6 were used for the analysis because 
this region was found in all alternatively spliced transcripts, as well as in all viral TAPAS 
RNA fused transcripts, suggesting it may have functional importance. Regions 
homologous to the TAPAS gene exons 4-6 and intervening introns, were identified in 
various avian genomes by BlastN, and the sequences were aligned by ClustalX.  It was 
observed that this region is highly conserved at the sequence level in many, but not all, 
avian lineages (Figure 6.6).  Additionally, based on transcriptome analysis, there exists a 
predicted lncRNA in the TERT promoter region in the most recent genome assemblies 
for chicken (LOC107052651), turkey (LOC104910189) and Japanese quail 
(LOC107309454) (data not shown). The chicken sequence shared 95% identity with the 
corresponding genomic region of the closely related black grouse (Lyrurus tetrix), and 
72-76% identity with the genomes of various neoavian lineages.  The turkey and chicken 
sequences share limited similarities in exons 4-6, but have significant sequence homology 
in exon 7. The only perching bird species in which this region was conserved was the 
most basal species of New Zealand wren (Acanthisitta chloris) suggesting the possibility 
that these sequences underwent rapid evolutionary changes in Passseriformes. The ORF 
in exons 4 and 5 was not conserved in most birds (data not shown).  Further, we did not 
find any regions homologous to the chicken TAPAS RNA in mammalian genomes at the 
sequence level. Exon 6 was the most conserved in avian species with 72-96% identity. 
The splice donor sites of exon 5 as well as the donor and acceptor sites of exon 6 are 





Figure 6.6: TAPAS gene is conserved in avian species. Phylogenetic analysis of exons 
4-6 and the intervening introns of the TAPAS gene, in several different avian species. 










TAPAS RNA regulates TERT expression  
We reasoned based on the correlation of TERT and TAPAS expression in tissue and 
throughout development, that TAPAS might be regulating TERT. Recruiting chromatin 
remodelers is a commonly reported function of lncRNAs and would provide a 
mechanism by which TAPAS could be regulating TERT. To answer this, we cloned 
shRNA constructs targeting TAPAS into a viral vector. Transfection of chick embryonic 
fibroblasts (CEF) with the shRNA construct against TAPAS generated a robust knockout 
of approximately 5-fold. In these cells, TERT expression also decreased significantly by 
10-fold (Figure 6.7). This provides evidence that TAPAS could potentially play a role in 
regulating TERT expression. 
We believe this regulation occurs in cis- because when the viral fusion truncated 
TAPAS transcript is overexpressed in trans-, there is no significant effect on TERT 
expression (Figure 6.8A). Neither the overexpression nor knockout of TAPAS expression 
caused any significant changes in cell proliferation, resistance to apoptosis, or migration. 
Interestingly, when TAPAS exons 4-7 are overexpressed in trans in CEF cells, there 
appears to be a negative effect on immortalization suggesting that TAPAS may promote 
senescence (Figure 6.8B). However, because TERT expression is not affected, the 
mechanism behind this observed senescence is unclear. Further, this promotion of 









Figure 6.7: TAPAS RNA knockdown affects TERT expression. (A) shRNA 
transfection in chick embryo fibroblasts (CEF) decreased TAPAS expression by 
approximately 5-fold relative to a scrambled control. TERT mRNA expression decreased 









Figure 6.8: Overexpression of TAPAS exons 4-7 does not affect TERT expression 
but does promote senescence in chick embryo fibroblasts. TAPAS exons 4-7 cDNA 
was cloned into RCAS(A) viral vector to mimic the truncated viral fusion transcript being 
overexpressed in tumors. Cells were infected with either the RCAS(A) viral vector 
carrying TAPAS or an empty RCAS(A) vector as a control. TAPAS was successfully 
overexpressed  approximately 350,000-fold relative to uninfected CEF cells. (A) TERT 
mRNA expression in cells overexpressing TAPAS RNA was not elevated above 
uninfected CEF cells. (B) Immortalization assay. CEF cells typically senesce after 30 
days. Shown is a growth curve measured after this time point, from days 39-53. The 




Humans have a similar TAPAS RNA transcript that regulates TERT expression 
 To determine if humans have a similar TAPAS RNA transcript, we analyzed 
publicly available RNA-seq data from ENCODE. We found a region upstream of the 
TERT promoter that is transcribed in a number of cell lines including GM12878, a 
human B-cell line, and HepG2, a hepatocellular carcinoma line. Similar to chickens, this 
transcript is antisense. We further analyzed CAGE (Cap Analysis of Gene Expression) 
data to determine the 5’ end of the transcript. CAGE involves pulling down expressed 
mRNAs by the 5’ cap allowing for sequencing and identification of the transcription start 
site of individual mRNAs. From these datasets, we detected a distinct peak for this 
transcript that begins about 170 nt upstream of the TERT TSS (Figure 6.9). We verified 
this transcript in various cell lines, such as HEK293T and HeLa, using RT-PCR. We 
were able to verify a 1.6 kb transcript that is unspliced. The human transcript shares no 
sequence homology to the chicken transcript. It also has no significant ORFs indicating 













Figure 6.9: A similar antisense lncRNA transcript can be detected in human cells. 
Total RNA-seq data from GM12878 cell lines was used to determine transcription in the 
region. Transcription is shown as a BedGraph in the top two tracks. Reads shown in 
green map to the TERT transcript. Reads shown in blue map in the opposite 
transcriptional orientation of TERT. The bottom two tracks show CAGE data from the 
same GM12878 cell line. Distinct peaks can be seen at the 5’ end of TERT as well as the 







To determine if the putative hTAPAS transcript has a similar role in regulating 
TERT expression, we made use of antisense oligonucleotides targeted against human 
TAPAS. TAPAS mRNA levels decline approximately 10-fold relative to a scrambled 
control when treated with the targeted antisense oligonucleotide. TERT expression 
consequently increased 2.2-fold relative to scrambled indicating that TAPAS may 
similarly be playing a role in regulating TERT mRNA expression (Figure 6.10A). To 
determine if hTAPAS is involved in cancer, we analyzed patient transcriptome data from 
various cancers from The Cancer Genome Atlas (TCGA). Interestingly, we found that 
hTERT and hTAPAS are typically not co-expressed in agreement with in vitro knockdown 












Figure 6.10: hTAPAS may regulate hTERT expression. (A) An antisense 
oligonucleotide targeting hTAPAS was used to knockdown hTAPAS levels approximately 
10-fold relative to a scrambled control. TERT expression subsequently increased 
approximately 2-fold (n=3, p<0.05). (B) hTERT and hTAPAS expression levels in 
patients with various cancers were determined from RNA-seq data from TCGA. 
Expression of hTERT and hTAPAS in patients expressing either of these genes is shown 
as a heat map with higher expression (FPKM) corresponding to darker red color and 
lower expression shown as lighter color. hTAPAS expression is shown on the top track 
while TERT expression is shown on the bottom track. Data is separated by cancer type. 



















6.3 Discussion  
In order to better understand tumor pathogenesis, we analyzed the distribution of 
ALV integration in chicken B cell lymphomas using a high throughput sequencing 
strategy. We identified numerous clonally expanded proviral integrations in the TERT 
promoter region suggesting these integrations may promote tumorigenesis. Previous 
studies have also reported proviral integrations of ALV, hepatitis B and papilloma virus 
in the TERT promoter region that induced elevated TERT expression, with similar 
implications in tumorigenesis (Ferber et al., 2003; Li et al., 2014; Yang et al., 2007b). 
However, in our work we show that the proviral integrations in our tumors are antisense 
to TERT and are driving the over-expression of a novel lncRNA, which we’ve named 
TAPAS (TERT antisense promoter-associated) RNA. Retroviral activation of a birectional 
promoter-associated lncRNA has not been previously reported. The prevalence of 
integrations in the same orientation to the TAPAS RNA in multiple tumors suggests that 
over-expression of this transcript may have made cells predisposed to oncogenic 
transformation and proliferation. We also find evidence for a similar upstream antisense 
transcript in human cell lines.  
The detected TERT promoter associated transcripts in chickens and humans vary 
significantly. No conservation was detected at the sequence level. The chicken transcript 
contains 7 exons and is alternatively spliced whereas only one, unspliced exon has been 
detected in the human transcript. Similar to the chicken transcript however, the human 
transcript has no significant ORFs and no protein domain homology indicating that it is 




Many lncRNAs are known to play a role in transcriptional regulation. For 
example, XIST acts in cis to recruit the polycomb repressive complex 2 (PRC2) to 
chromosome X causing gene silencing (Zhao et al., 2008). HOTAIR on the other hand 
acts in trans to repress the expression of genes in the HoxD gene cluster (Gupta et al., 
2010). It has been proposed that antisense lncRNAs transcribed from bidirectional 
promoters may be involved in regulation of the associated sense transcripts (Wakano et 
al., 2012; Wei et al., 2011). Such an arrangement may allow for tighter transcriptional 
regulation. Based on the correlation between TERT and TAPAS RNA expression in adult 
tissues, we hypothesized that TAPAS may be regulating TERT expression.  
Consistent with this idea, knockdown of TAPAS lncRNA expression in cis- 
affected TERT mRNA expression. In CEF cells, knockdown of TAPAS caused a decrease 
in TERT expression, while in humans, hTAPAS knockdown caused a subsequent increase 
in TERT expression. Thus, while it seems that TAPAS is affecting TERT expression, it is 
unclear how it is doing so. However, we do believe this regulation is likely occurring in 
cis- as episomal over-expression of the truncated viral fusion TAPAS transcript had no 
impact on TERT expression. It is also possible that TERT and TAPAS expression are only 
correlated due to mutual regulation by the bidirectional promoter. This opens the 
possibility that TAPAS RNA may have an independent function apart from that of TERT 
regulation. 
Given the important role of lncRNAs in transcriptional regulation, it comes as no 
surprise that many lncRNAs have been implicated in cancer and disease. With the advent 
of deep sequencing, an increasing number of lncRNAs have been identified that have 




tumorigenesis and cancer pathogenesis. For example, BIC was first identified as a non-
coding RNA up regulated in ALV induced lymphomas and was later found to be the 
precursor of the oncogenic microRNA mir-155 (Clurman and Hayward, 1989). Other 
well-studied lncRNAs, such as HOTAIR, MALAT1, PCAT-1, PCGEM1, TUC338 were 
reported as oncogenes, while GAS5, MEG3 and PTENP1 were reported as tumor 
suppressors (Braconi et al., 2010; Gibb et al., 2011; Gupta et al., 2010; Gutschner et al., 
2013; Huarte et al., 2010; Mourtada-Maarabouni et al., 2009; Poliseno et al., 2010; 
Prensner et al., 2011; Zhang et al., 2010). Since lncRNA functions range from cell 
growth to cancer development, they represent important biological players that merit 
further research.  
We have identified novel antisense lncRNAs transcribed from the TERT promoter 
in chickens and humans. We show that these lncRNAs are up regulated in cancer and 
implicated in tumorigenesis. We also show that they may play a role in regulating TERT 
mRNA expression. Further characterization of the structural and functional motifs of 
these lncRNAs is required to better understand its mechanistic and functional role in 
cancer signaling. This will help elucidate possible gene regulatory mechanisms of 




































7.1 Regulation of ALV integration 
 We provide here strong evidence that the FACT complex directly binds ALV 
integrase and regulates ALV integration efficiency in vitro and in vivo (Chapter 3). 
However, the evidence that the FACT complex is also playing a role in targeting of ALV 
integration is less robust. We do observe that knockout of the FACT complex causes a 
significantly decreased frequency of integration in the proximity of the transcription start 
site (TSS). Data from FACT complex chromatin binding in human cells indicates that the 
FACT complex is enriched at the TSS, thus this may indicate that the FACT complex is 
recruiting the ALV integration complex to its chromatin binding sites. Performing 
integration mapping in wild type human cells as well as in cells with functional FACT 
complex and cells in which the FACT complex has been depleted would allow 
correlation of integration sites with FACT complex ChIP-seq data to determine if FACT 
binding sites overlap with integration sites. This would allow the question of the 
mechanism of FACT targeting to be more thoroughly addressed. 
 Further, integration of ALV into satellite sequences also correlates with FACT 
complex levels. In the absence of FACT complex, there appears to be significantly more 
integration into satellite sequences. With the limited amount of information available on 
the chicken genome it was not possible to determine what these satellite sequences were. 
We hypothesize that these satellites might be a general marker of heterochromatin and 
that the absence of the FACT complex results in more integration into heterochromatic 
regions. Again, experiments in human cells in which information on heterochromatin and 




modifications with integration site location may reveal more differences in integration 
targeting that we are unable to detect in chicken cells. 
 Our data seems to suggest that the BET proteins may also play a secondary role in 
regulating and/or targeting ALV integration. However, this regulation seems to be 
opposite in nature to that observed for the FACT complex. While the FACT complex 
promotes ALV integration efficiency, BET proteins inhibit integration. We believe that 
the role of BET proteins is secondary due to the primary effect of the FACT knockout on 
ALV integration efficiency, in addition to the observation that BET protein inhibition 
affects ALV integration pattern more appreciably in the absence of functional FACT 
complex. 
 Binding of BET proteins to the ALV integrase protein needs to be evaluated to 
determine if the binding is direct. Once this is determined, competition between FACT 
complex and BET protein binding can be assessed. In vitro integration assays of BET 
proteins alone as well as in conjunction with the FACT complex would also be useful in 
developing a model for ALV integration regulation. Evaluating the integration pattern of 
ALV in human cells would also be helpful. The chicken genome is poorly annotated and 
there is little additional data on histone modifications or transcription factor binding sites. 
Having integration data in human cells in which FACT and/or BET proteins have been 
depleted or inhibited would allow correlation of integration pattern with many additional 
genomic features.  
The fact that ALV integration is relatively random may also make it difficult to 




certain host cell factors do indeed play a role in targeting via a bimodal tether model, 
chimeric factors could be constructed to achieve retargeting. 
Lastly, our screen to identify integrase binding partners is limited. We make the 
assumption that the host cell factor responsible for regulation or targeting of ALV binds 
the integrase protein alone. In vivo, the integrase protein is not present in isolation. 
Instead it is complexed with viral DNA, as well as other viral proteins such as 
nucleocapsid and capsid, within the pre-integration complex (PIC). Thus, it is possible 
that our screen is not detecting all cooperating host cell factors. To further complicate the 
matter, the integrase protein is also extensively modified post-translationally which could 
alter the repertoire of host cell proteins that it is capable of binding (Cereseto et al., 2005; 
Zheng and Yao, 2013). Thus, modifying the screen to be more similar to the in vivo 
context of the integration complex may be able to reveal more regulatory host cell 
factors. 
7.2 Function of CTDSPL and CTDSPL2 in oncogenesis 
While previous studies have characterized CTDSPL as a tumor suppressor gene, 
our studies indicate to the contrary that both CTDSPL and CTDSPL2 have oncogenic 
properties. In the tumors, ALV integrations into these genes generate truncated viral 
fusion transcripts. It is unclear exactly what the truncation is doing to alter the function of 
the proteins and why these truncated products have been selected for in tumors. 
Expression of truncated constructs uniquely promotes immortalization, a function not 
observed when the full-length proteins are expressed alone. The portions of the proteins 
that are truncated contain an intrinsically disordered region that could potentially play a 




CTDSPL has been reported to act as a phosphatase on pRb (retinoblastoma 
protein), a well-studied tumor suppressor gene. By dephosphorylating pRb, CTDSPL 
keeps it in an active form. We hypothesize that the truncated proteins are no longer able 
to interact with pRb and thus pRb becomes inactivated allowing for avoidance of 
senescence. To test this hypothesis, we could analyze phosphorylation status of pRb in 
vivo in the presence of the truncated proteins as opposed to the full-length proteins. 
Immunoprecipitation of full length and truncated proteins from cell extracts could also be 
used to determine differential binding partners which could help elucidate the function of 
the truncated protein. 
7.3 Function of chicken and human TAPAS RNA 
We show here preliminary data on the function of TAPAS RNA in regulating 
TERT expression. We find that chicken and human TAPAS seem to regulate TERT 
mRNA expression in opposite directions. It is unclear whether this is a species specific or 
cell-type specific effect. Of note, the chicken knockdown experiments were performed in 
a primary cell line whereas the human knockdown experiments were done in an 
immortalized cell line (HEK293T). Preliminary data not shown here indicates that in a B-
cell lymphoma derived chicken cell line (DT40s), knockdown of TAPAS may cause an 
increase in TERT expression similar to that observed in the HEK293T cell line. Thus, it 
is possible that TAPAS may function differently in primary vs. immortalized or cancer-
derived cells. It would be useful to perform TAPAS RNA knockdown experiments in 
more cell types of each species to determine whether the effect is cell-type specific. The 
mechanism by which TAPAS RNA is regulating TERT expression is not clear. We 




chromatin remodeling at the adjacent TERT promoter. Moreover, to narrow down the 
function of TAPAS RNA, we could perform RNA immunoprecipitation from cell 
extracts to determine what TAPAS is binding. This could determine what, if any, 
chromatin remodelers TAPAS is binding and potentially recruiting. We could then 
subsequently look at histone modifications and/or DNA methylation at the TERT 
promoter in the presence and absence of TAPAS RNA expression to determine if TAPAS 
does indeed modify the chromatin status. 
Further, we have only explored the hypothesis that TAPAS regulates TERT 
mRNA expression. It is possible that TAPAS RNA could be regulating other cellular 
genes or processes. To determine if this is the case, we could overexpress or knockdown 










































Cell culture and viruses 
DT40 cells were cultured in Dulbecco’s modified eagle medium (DMEM; 
Thermo Fisher Scientific), 10% fetal calf serum, 5% chicken serum, 5% tryptose 
phosphate and 1% antibiotic at 37°C and 5% CO2 (Winding and Berchtold, 2001). CEF 
cells were cultured in media 199 (Thermo Fisher Scientific) supplemented with 2% 
tryptose phosphate, 1% fetal calf serum, 1% chicken serum and 1% 
antibiotic/antimycotic at 39°C and 5% CO2. HEK293T cells were cultured in Dulbecco’s 
modified eagle medium, 10% FBS and 1% antibiotic at 37°C and 5% CO2.  HEK293T 
cells were cultured in Dulbecco’s modified eagle medium (Thermo Fisher Scientific) 
supplemented with 10% fetal bovine serum at 37°C and 5% CO2. 
SSRP1 conditional knockout cells (SSRP1
-/-
 + SSRP1) were obtained as a gift 
from Dr.Takemi Enomoto, Tohoku University (Abe et al., 2011). This cell line was 
generated by knocking out both endogenous SSRP1 loci in an otherwise wild type DT40 
background. A Flag-tagged wild type copy of the chicken SSRP1 gene was introduced 
under the control of a tet-repressible promoter. To induce knockout, cells were pre-
treated with 1 µg/mL doxycycline for 24 hours before infection. Knockout was verified 
by qRT-PCR or Western blot prior to infection using a Flag antibody (8146, Cell 
Signaling Technology).  
ALV was generated by transfecting CEF cells with RCASBP(B), RCASBP(C) or 
RCASBP(C)-eGFP plasmid (Hughes, 2004) using electroporation. Viral supernatant was 
collected and filtered through a 0.22 micron filter. To generate MLV and HIV-1 
pseudotyped with vesicular stomatitis virus G glycoprotein (VSV-G), NIH-3T3 or 




(VSV-G envelope plasmid) (Burns et al., 1993) and either MLV (pNCS) (Gao and Goff, 
1998) or HIV plasmid (pNL4-3ΔE-GFP) (Zhang et al., 2004) respectively. Viral 
supernatant was collected after 48 hours, filtered through a 0.22 micron filter and 
concentrated by PEG precipitation (10% PEG 8000) (Cepko et al., 2001). 
Reverse transcriptase assay for viral detection 
 Viral supernatant was collected from infected cells by removing cellular media 
and centrifuging to remove cells. Viral supernatant was then mixed with a cellular RNA 
template, random hexamer primer, dNTPs, and RT buffer (20 mM MgCl2, 0.2% Triton-X 
100, 2 mM EDTA, 100 mM Tris, pH 8.0). The mixture was incubated for 1 hour at 37°C. 
Samples were then diluted 2-fold and 1 uL of reaction is used in a standard SYBR Green 
qPCR reaction with primers against a housekeeping gene.  
siRNA, shRNA and antisense oligonucleotide mediated gene knockdown 
 siRNA against NCL and UBTF were used to knockdown these genes in 
HEK293T cells. siRNA sequences can be found in Appendix 1. HEK293T cells were 
transfected using FuGene 6 (Promega). chTAPAS was knocked down using cloned 
shRNA, the sequences of which can be found in Appendix 1. shRNA were cloned into 
RCAS(A) vector. Virus was produced in CEF cells and subsequently used to transmit the 
shRNA to experimental cells. hTAPAS was knocked down in HEK293T cells using 
antisense oligonucleotides delivered using FuGene 6 for transfection. 
Nucleic acid extraction 
Genomic DNA was isolated using a DNeasy Blood & Tissue kit (Qiagen). RNA was 
extracted from tissue homogenates using RNA Bee extraction agent (Tel-Test, Inc, 




Integration site mapping high throughput sequencing library preparation and analysis 
 Genomic DNA for ALV integration mapping libraries was collected using standard 
proteinase K digestion followed by phenol-chloroform extraction (Yang et al., 2007b). 
Libraries were prepared and analyzed using a custom pipeline as described previously 
(Justice et al., 2015a). Integrations were attributed to the nearest RefSeq gene. To analyze 
integration pattern into various genomic annotations as well as around TSS we made use 
of HOMER bioinformatics tools (Heinz et al., 2010). Integration frequency in proximity 
to CpG islands was calculated using BedWindow (Quinlan and Hall, 2010).  
Transcriptome profiling and analysis 
RNA-Seq libraries were prepared in duplicate using the TruSeq stranded mRNA 
library kit according to manufacturers directions and sequenced on the Illumina HiSeq 
platform. Differential gene expression was determined using Cufflinks (Trapnell et al., 
2012). Genes with a 2-fold or greater difference in gene expression were considered for 
further analysis. Gene ontology (GO) analysis was performed using g:Profiler and 
DAVID (Huang et al., 2009; Reimand et al., 2007). GO terms with a p-value of less than 
0.05, after Bonferroni correction for multiple testing, were considered significantly 
enriched above background. 
Additional RNA-Seq data for analysis of tissue distribution and embryonic 
expression of TAPAS RNA and TERT in chickens were downloaded from the public 
sequence read archive (SRA) database (SRA Accession no. ERX697750 and 
DRX001564) (Leinonen et al., 2011). Abundance of transcripts (FPKM) was estimated 




Recombinant proteins, affinity pull-down and MS-based proteomics to identify integrase 
binding factors.  
6xHis-tagged HIV-1 IN, GST-tagged HIV-1 IN and 6xHis-tagged MLV IN were 
purified as previously described (Larue et al., 2014; McKee et al., 2008). Full length 
GST-tagged ALV IN was made synthetically in pGEX-6P-1 by GenScript and truncated 
by site directed mutagenesis to add a stop codon at codon 51 and 208 (generating GST-
tagged ALV NTD IN and GST-tagged ALV NTD/CCD IN respectively).  ALV IN 
constructs were purified similarly to HIV-1 IN with either a HisTrap HP column 
followed by Heparin column or Glutathione Sepharose column (all from GE Healthcare).  
The FACT proteins were purified as described (Winkler et al., 2011). 
To identify cellular proteins selectively interacting with ALV IN, in parallel 
reactions we used recombinant ALV and HIV-1 INs as baits to capture their binding 
partners from cellular extracts. Affinity pull-down experiments were performed with 
GST- and 6xHis-tagged proteins using glutathione sepharose 4B and nickel affinity beads 
(GE Healthcare), respectively. Buffer conditions were 25 mM Tris (pH 8.0), 200 mM 
NaCl, 0.1% Nonidet P-40, 2 mM β-mercaptoethanol, and 1×complete protease mixture 
(Roche) or 50mM TrisHCl pH 7.5, 250mM NaCl, 2 mM β-mercaptoethanol, and 
1×complete protease mixture (Roche), respectively for nickel and GST beads. Sup-T1, 
DT40 or 293T nuclear extracts were prepared using the NE-PER Nuclear and 
Cytoplasmic Kit (Thermo Scientific) and incubated with the prebound beads and the 
bound proteins were separated by SDS-PAGE.  Samples were either subjected to 
immunoblotting using SSRP1 (ab137034, Abcam) or Spt16 (sc-28734, Santa Cruz) 




For MS experiments, entire lanes were excised, subjected to in-gel trypsin 
digestion and the resulting peptides were analyzed with capillary-liquid chromatography 
– tandem MS/MS using a Thermo Finnigan LTQ Orbitrap mass spectrometer equipped 
with a microspray source (Michrom Bioresources).  We performed two sets of pull-
downs from nuclear extracts of DT40 and Sup-T1 cells for the MS experiments. Human 
Sup-T1 cells were used in addition to chicken DT40 cells because the MASCOT search 
engine allows for peptide mass fingerprinting using Homo sapiens (human) but not 
chicken taxonomy. This is because the chicken genome is currently not completely 
structurally and functionally annotated (based on Gene Ontology) and many of the genes 
have not yet been assigned standard nomenclature. Therefore, to identify the peptides 
from DT40 cells we used the higher order “bony vertebrate” classification. For both set 
of pull-downs; unique proteins (those with a spectral count greater than 5) were identified 
that bound either HIV-1 or ALV IN, compared between cell types and only those that 
were reproducible unique hits were selected for further analysis.  LEDGF/p75 served as a 
control as it is known to selectively bind HIV-1 IN. 
Integrase binding experiments 
Recombinant protein pull-downs were performed with purified GST-tagged HIV-
1 or ALV INs as well as the ALV IN domains (1 µM) prebound to glutathione sepharose 
4B beads (GE Healthcare) in 50mM TrisHCl pH 7.5, 250mM NaCl, 2 mM β-
mercaptoethanol, and 1×complete protease mixture (Roche).  Purified SSRP1, Spt16 or 
the FACT complex (0.6 µM) were added to the beads, and the bound proteins were 
separated by SDS-PAGE and visualized by Coomassie staining. 




HIV-1 or ALV IN strand transfer activities were assayed using similar 
homogenous time-resolved fluorescence (HTRF)-based strand transfer assays developed 
for HIV-1 and MLV IN (Kessl et al., 2012; Sharma et al., 2013). The assays contained 5′-
Cy5–labeled viral donor DNA (200 nM) (ALV Don1: 
/5Cy5/ACGAGCACAGGAGTATGGATGACGACAACATT, ALV Don2: 
/5Cy5/AATGTTGTCGTCATCCATACTCCTGTGCTCGT), biotin-labeled target DNA 
(20 nM) (Ace1: ACAGGCCTAGCACGCGTCG/3’Bio/, Ace2: 
CGACGCGTGCTAGGCCTGT/3’Bio/), purified recombinant His-tagged ALV IN or 
HIV-1 IN (400 nM) and purified recombinant SSRP1, Spt16, or FACT complex (1 µM) 
to the respective reactions containing IN, donor (HIV-1 or ALV specific), and target 
DNA substrates. The strand-transfer products were detected after addition of europium 
chelate–streptavidin Lance reagent (2 nM; PerkinElmer). The HTRF signal was recorded 
using a Perkin-Elmer Multimode Enspire plate reader using 314 nm for excitation 
wavelength and 668 and 620 nm for the wavelength of the acceptor and donor emission, 
respectively. 
Quantification of mRNA expression levels 
Reverse transcription was performed with Maxima H Reverse Transcriptase 
(Thermo Fisher Scientific) using an oligo(dT)18 and random hexamer primer. 
Quantitative PCR reactions were performed with the CFX96 Real Time System (Bio-
Rad) and prepared using PowerUp SYBR Green Mastermix (ThermoFisher Scientific) 
according to the manufacturer’s protocol on a BioRad C1000 thermocycler / CFX96 
Real-Time System. qPCR was performed in triplicate and analyzed using the comparative 




Quantification of proviral integration and other viral intermediates. 
To quantify proviral integrations, genomic DNA was purified by gel purification. 
Total DNA was loaded on a 0.5% low melting point agarose gel and run at 100V for 3 
hours. The high molecular weight band was then purified using a QiaEx II gel 
purification kit (Qiagen). The purified gDNA was then subjected to qPCR analysis with 
viral specific primers (ACATCCTTCTGACCGACCCA, 
CAATTCTGTCTCATTTGGGAGCAA) or from unpurified DNA using a CR1-gag 
nested PCR approach. In this approach, a PCR reaction was performed using a forward 
primer in the CR1 repeat element (N(8)ATTCTRTGATTCTRT) and a reverse primer in 
the gag gene of ALV (TAGGTTTTACACGCGGACGA). The product of this reaction 
was used as a template for a qPCR reaction with viral specific primers located in the LTR 
(ACCGTTGATTCCCTGACGAC, TGGCCGACCACTATTCCCTA). 
 2-LTR circles were detected by qPCR using primers spanning the LTR-LTR 
junction (GACTACGAGCACCTGCATGA, TCTCCTTGTAAGGCATGTTGCT). Plus 
strand extension products were quantified with gag forward and reverse primers 
(CTTGGGGAGTCCAACTCCAG, AGCCGGGCAACTTCTCTAAA). MLV and HIV-1 
integrations were quantified with viral specific primers from gel purified genomic DNA 
(MLV gag: TCAGGTCGGGCCACAAAAAC, ACTAGCTCTGTATCTGGCGGA; 
HIV-1 eGFP: ATCATGGCCGACAAGCAGAA, TCTCGTTGGGGTCTTTGCTC). 




All of the B-cell lymphomas included in this study were rapid-onset lymphomas 




chicken embryos, as described previously (Polony et al., 2003). LR-9 is an ALV 
subgroup A recombinant virus consisting of gag, pol, and env genes derived from UR2 
associated virus and LTRs derived from ring-necked pheasant virus (Simon et al., 1987). 
Tumors were collected from primary bursal (B) tumors or metastasized liver (L) tumors. 
A1B was induced by ΔLR-9, with a deletion in the gag gene, causing increased splicing 
to downstream genes (Smith et al., 1997). Tumors C2B, C2L, C6L, C7B and C7L were 
induced by infection with LR-9 containing a silent mutation, G919A, which induces a 
higher incidence of rapid-onset lymphomas (Polony et al., 2003), probably due to 
increased readthrough and splicing to downstream genes (O’Sullivan et al., 2002). Tumor 
D2L was induced by WT LR-9 (Simon et al., 1987).   
Detection of viral fusion transcripts 
RNA was extracted using RNA-Bee reagent (Tel-Test, Inc.). cDNA was prepared using 
Maxima H reverse transcriptase with an oligo(dT)18 primer (ThermoFisher Scientific). 
Fusion transcripts were detected by performing PCR with a forward primer in gag 
immediately before the viral splice donor (TCAAGCATGGAAGCCGTCATAAAG) and 
a reverse primer within the gene of interest (CTDSPL: TGAAAATGCAGTGCCTGTGC; 




Proliferation and apoptosis assay. 
 Cells were seeded at 0.8 x 10
6
 cells in a 10 cm dish at time 0. To induce 




hours, cells were collected and counted using a BioRad automated cell counter (BioRad 
TC20) to determine change in cell survival relative to CEFs infected with empty viral 
vector. Population doublings were calculated from total live cell count at day 2 relative to 
day 0. Proliferation was then plotted relative to CEFs infected with empty viral vector as 
a control condition. Significance was assessed using an unpaired t-test.  
Scratch assay. 
 A scratch assay was used to detect differences in cell migration as described 
previously (Liang et al., 2007). Cells were seeded in 6-well plate at 3x105 cells per well 
and allowed to grow for approximately 24 hours or until cells were 100% confluent. The 
plate of cells was then scratched with a P200 tip at time 0. Closure of the scratch was 
monitored via light microscopy for 8 hours. Migration of cells into scratch was quantified 
using ImageJ (Abramoff et al.). 
Evolutionary analysis of TAPAS RNA 
The sequence encompassing exons 4-6 and intervening introns of chicken TAPAS gene 
was analyzed via BlastN against the whole genome shotgun database at the NCBI web 
site (http://blast.ncbi.nlm.nih.gov/). All high quality matches with an E-value lower than 
10
-40
 were retrieved and further analyzed. Sequences were aligned and plotted via the 
maximum-likelihood method, by PhyML, utilizing the GTR substitution and aBayes 







Appendix I: Primers and oligonucleotide sequences 
SSRP1 F GGCTCACCAAGAACATGTCA qPCR primer for 
chicken SSRP1 
SSRP1 R AGTCCTGAGCTGGCCTTGTA qPCR primer for 
chicken SSRP1 
SW20 N(8)ATTCTRTGATTCTRT CR1 nested PCR 1 
SW23 TAGGTTTTACACGCGGACGA CR1 nested PCR 1 
SW29 ACCGTTGATTCCCTGACGAC CR1 nested PCR 2 
SW30 TGGCCGACCACTATTCCCTA CR1 nested PCR 2 
SW39 TCTCCTTGTAAGGCATGTTGCT ALV 2LTR qPCR  
SW40 AACGCCATTTGACCATTCACC ALV 2LTR qPCR 
SW87 ACCTGGGGATTGGTTTTGGG ALV PSE qPCR 
SW88 TGGTTTCTCGATGCACTCCG ALV PSE qPCR 
SW53 GCCACTGTCGTTAGTGGACA MLV 
quantification 
SW54 AATCTTTAGCCCAGTGCCCC MLV 
quantification 
SW50 ATCATGGCCGACAAGCAGAA HIV-GFP 
quantification 
SW51 TCTCGTTGGGGTCTTTGCTC HIV-GFP 
quantification 
SW199 CACATGGTCCTGCTGGAGTT Sequencing primer 
in RCAS(C)-GFP 
Hs.Ri.NCL.13.1 AUAUUGAAUUUAAGACAGAAGCUGA Human NCL 
targeting siRNA 1 
Hs.Ri.NCL.13.2 CCGUGUUGGUUUUGACUGGAUAUTC Human NCL 
targeting siRNA 2 
Hs.Ri.NCL.13.3 UCUCUUUGUUGGAAACCUAAACUTT Human NCL 
targeting siRNA 3 
Hs.Ri.UBTF.13.1 GUCAUGUCACUGACCUAUUAAAUTG Human UBTF 
targeting siRNA 1 
Hs.Ri.UBTF.13.2 AACCAAGAUUCUGUCCAAGAAAUAC Human UBTF 
targeting siRNA 2 
Hs.Ri.UBTF.13.3 CGUGCAGCAUAUAAAGAGUACAUCT Human UBTF 
targeting siRNA 3 
SW293 TTGAGGGCAGAGCAATCAGG Human NCL qPCR 
SW294 AGAGTTTTGGATGGCTGGCT Human NCL qPCR 
SW297 GCCATCTCGGGCTTTGTCT Human UBTF 
qPCR 
SW298 CAAAGCCACCTCACCCGAG Human UBTF 
qPCR 
RB CTDSPL F TCTTCAAAGGATGGGAGAGC CTDSPL qPCR 




SW243 CCCCGCGAACTACCTTACTG CTDSPL2 qPCR 
SW244 CAGCCTCAACAGCTTGTCCT CTDSPL2 qPCR 
SW74 GTAAGACTAAGCCGTGTTGTTG chTERT qPCR ex5 
SW75 CTCCGAATACTGAAGAGC chTERT qPCR ex6 
SW70 AACATGAAATGCAAATTGACTGC chTERT qPCR 
ex11 
SW71 ACTGTCTGAAGGCTGTTGATCT chTERT qPCR 
ex12 
SW62 CAGACTACTTTACCTCTTGACACAG chTAPAS qPCR 
ex4 
SW63 ATGGTGAGCCTTGTGTTGGC chTAPAS qPCR 
ex5 
SM50 GTGCTGCAGCTCCCATTTCAT hTERT qPCR 
SM51 GCTTTCAGGATGGAGTAGCAGA  hTERT qPCR 
SW150 TGTAGCTGAGGTCGGCAAAC hTAPAS qPCR 
SW151 GGTGCGAGGCCTGTTCAAAT hTAPAS qPCR 
JJ227 TGCCATCACAGCCACACAGAAG GAPDH qPCR  
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